NCTNumber,Title,Acronym,Status,Conditions,Interventions,OutcomeMeasures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,FundedBys,StudyType,StudyDesigns,OtherIDs,StartDate,PrimaryCompletionDate,CompletionDate,FirstPosted,ResultsFirstPosted,LastUpdatePosted,Locations,Rank,StudyDocuments,StudyResults,URL
NCT04073472,Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's,IPAAF,Not yet recruiting,"Crohn's Disease|Fistula|Anal Fistula|Pouch, Ileal|Pouches, Ileoanal",Drug: mesenchymal stem cells (MSCs),Safety and Feasibility: Number Of Adverse Events|Radiographic Healing|Clinical Healing,The Cleveland Clinic,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,15.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IPAAF IND# IRB# are pending,"November 1, 2019","November 1, 2021","November 1, 2022","August 29, 2019",,"August 29, 2019","Cleveland Clinic, Cleveland, Ohio, United States",1,,No Results Available,https://ClinicalTrials.gov/show/NCT04073472
NCT02804945,Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies,,Completed,Blood And Marrow Transplantation|Adult Respiratory Distress Syndrome,Biological: Mesenchymal Stem Cells (MSCs),Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD),M.D. Anderson Cancer Center|Katz Foundation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0327|NCI-2016-01184,"February 24, 2017","June 13, 2019","June 13, 2019","June 17, 2016",,"August 26, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",2,,No Results Available,https://ClinicalTrials.gov/show/NCT02804945
NCT02866721,Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis,CEASE-CF,Recruiting,Cystic Fibrosis,Biological: Mesenchymal Stem Cells,"Dose limiting toxicity (DLT), triggered by occurrence in the first 24 hours after hMSC infusion of grade ≥3 infusion-related allergic toxicities|Incidence and severity of adverse events|Number of pulmonary exacerbations|Diary reports (Cystic Fibrosis Respiratory Symptom Diary (CFRSD))|Changes in subject reported symptoms as captured by the Respiratory Signs and Symptoms Questionnaire (RSSQ) from Baseline (Visit 2) Day 1 to Baseline (Visit 2) Day 2, Visits 3, 4, 5, 6 and 7 and at times when a pulmonary exacerbation is being considered|Changes in physical examination|Changes in vital signs including oxygen saturation checked throughout infusion|Changes in spirometry (FEV1 %, FEV1 (Liters), FEF25-75) determined 30 minutes, 4 hours, and 24 hours after completion of infusion and from Baseline (Visit 2) Day 1 to Visits 3, 4, 5, 6 and 7|Change in sputum quantitative microbiology (bacterial colony forming units between Baseline to Day 7 and Day 28)|Changes in hematology, comprehensive chemistry, ESR, hs-CRP, and urinalysis results|Change in blood inflammatory biomarkers from Baseline to Day 7 and Day 28|Change in sputum inflammatory biomarkers from Baseline to Day 7 and Day 28",Erica Roesch|Case Western Reserve University|Cystic Fibrosis Foundation|University Hospitals Cleveland Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,15.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Protocol CF-MSC-01|DASENB15A0,August 2016,December 2019,December 2020,"August 15, 2016",,"February 12, 2019","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",3,,No Results Available,https://ClinicalTrials.gov/show/NCT02866721
NCT02181712,Mesenchymal Stem Cell Therapy for Lung Rejection,,Recruiting,Lung Transplant Reject|Bronchiolitis Obliterans,Biological: Mesenchymal stem cell 0.5|Biological: Mesenchymal stem cell 1.0,Number of Participants with serious and non-serious adverse events|Changes in pulmonary function tests,Mayo Clinic,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,19.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-000025,July 2014,September 2020,September 2021,"July 4, 2014",,"September 25, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States",4,,No Results Available,https://ClinicalTrials.gov/show/NCT02181712
NCT04047810,Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD),,Recruiting,Chronic Obstructive Pulmonary Disease,Biological: Mesenchymal Stem Cells,Adverse Events,Mayo Clinic,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 1,15.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-007748,"November 15, 2019","August 16, 2021","August 16, 2021","August 7, 2019",,"October 10, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States",5,,No Results Available,https://ClinicalTrials.gov/show/NCT04047810
NCT02484950,Mesenchymal Stem Cell Augmentation in Patients Undergoing Arthroscopic Rotator Cuff Repair,,Recruiting,Full Thickness Rotator Cuff Tear,Biological: Mesenchymal stem cell augmentation in rotator cuff repair|Procedure: Standard arthroscopic rotator cuff repair,American Shoulder and Elbow Surgeons (ASES) Score|Magnetic Resonance Imaging (MRI) Scan|Functional Outcomes - Shoulder Exam|Patient Centered Outcomes - Shoulder Survey,Rush University Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",15042702,November 2015,November 2018,November 2020,"June 30, 2015",,"October 25, 2017","Rush University Medical Center, Chicago, Illinois, United States",6,,No Results Available,https://ClinicalTrials.gov/show/NCT02484950
NCT02315027,Mesenchymal Stem Cell Therapy in Multiple System Atrophy,,"Active, not recruiting",MSA,Biological: autologous mesenchymal stem cells,"Adverse event frequency (by severity, type, attribution, and intervention dose).|Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort).|Rate of change from baseline to 12 months (or last available date) in UMSARS II score.|Rate of change from baseline to 12 months (or last available date) in UMSARS total score.|Rate of change in COMPASS-select score from baseline to 12 months.|Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months.|MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months.|Change in CSF biomarkers from baseline to 2 months.",Mayo Clinic,All,"30 Years to 80 Years   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-005950|G4789,October 2012,August 2020,August 2020,"December 11, 2014",,"October 2, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",7,,No Results Available,https://ClinicalTrials.gov/show/NCT02315027
NCT02235844,Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD),,Completed,Duchenne's Muscular Dystrophy,Biological: Umbilical Cord Mesenchymal Stem Cells,Adverse Events|Change from baseline of weight|Change of muscle diameter (circumferential measurements) from baseline|Change from baseline of Pulmonary Maximum Expiratory Pressure|Change from baseline of Pulmonary Forced Vital Capacity|Maximum Change from baseline of Predicted Inspiratory Pressure %|Change from baseline of Predicted Maximum Expiratory Pressure %|Change from baseline of Predicted Forced Vital Capacity %,"Allergy and Asthma Consultants, Wichita, Kansas|Aidan Foundation|Neil H. Riordan PhD",Male,28 Years to 31 Years   (Adult),Phase 1,1.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IND 16026 DMD Single Patient,September 2014,"September 30, 2017","September 30, 2017","September 10, 2014",,"September 16, 2019","Asthma and Allergy Consultants, Wichita, Kansas, United States",8,,No Results Available,https://ClinicalTrials.gov/show/NCT02235844
NCT03570333,Progenitor Potential of Mesenchymal Stem Cells in Palatal Tissue Harvested From Molar and Premolar Sites,,"Active, not recruiting",Gingival Recession|Lack of Keratinized Gingiva (Disorder),Diagnostic Test: progenitor potential of Gingival Mesenchymal cells,Osteogenic potential|Adipogenic potential|Genotype assay,University of Alabama at Birmingham,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,10.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,GMC:18,"September 17, 2018",December 2019,December 2020,"June 26, 2018",,"July 19, 2019","UAB School of Dentistry Department of Periodontology, Birmingham, Alabama, United States",9,,No Results Available,https://ClinicalTrials.gov/show/NCT03570333
NCT02530047,Mesenchymal Stem Cells (MSC) for Ovarian Cancer,,Completed,Ovarian Cancer,Genetic: MSC-INFβ|Behavioral: Questionnaires,Maximum Tolerated Dose (MTD) of Mesenchymal Stem Cells-Interferon-β (MSC-IFNβ)|Correlation Between the Number of MSC-IFNβ Infused and the Production of Interferon-β and the Number of MSC-IFNβ Detected at the Tumor Sites Via Tumor Biopsy Pre- and Post-Treatment,M.D. Anderson Cancer Center,Female,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,5.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013-0032|CA 136411|NCI-2015-01504,"May 16, 2016","June 13, 2019","June 13, 2019","August 20, 2015",,"July 18, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",10,,No Results Available,https://ClinicalTrials.gov/show/NCT02530047
NCT03929120,Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD),,Recruiting,Interstitial Lung Disease|Connective Tissue Diseases,Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs),Adverse Events,Mayo Clinic,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,10.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-007216,November 2019,May 2020,December 2020,"April 26, 2019",,"October 10, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States",11,,No Results Available,https://ClinicalTrials.gov/show/NCT03929120
NCT01849887,Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke,,Withdrawn,Ischemic Stroke,Biological: bone marrow-derived mesenchymal stem cells|Drug: Placebo,Number of Adverse Events,"University of California, Irvine",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DR3-07521,January 2016,January 2016,January 2016,"May 9, 2013",,"January 22, 2016","University of California Irvine Medical Center, Orange, California, United States",12,,No Results Available,https://ClinicalTrials.gov/show/NCT01849887
NCT03487731,Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain,VALIANT,Not yet recruiting,Facetogenic Back Pain|Back Pain,Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Drug: Placebo,Incidence of any treatment-emergent serious adverse events|Difference in subject quality of life assessment - SF-12|Difference in subject quality of life assessment - Oswestry Low Back Pain|Death from any cause.|Change in pain using the Numeric rating scale,Joshua M Hare|University of Miami,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20180018,"December 1, 2019","December 1, 2025","December 1, 2025","April 4, 2018",,"July 23, 2019","ISCI / University of Miami Miller School of Medicine, Miami, Florida, United States",13,,No Results Available,https://ClinicalTrials.gov/show/NCT03487731
NCT03371329,Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage,,Recruiting,Hemorrhagic Stroke|Intracerebral Hemorrhage,Biological: MSC,Occurrence of adverse events|Changes in neurological function test,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,12.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-003524,"December 12, 2017","December 12, 2020","December 12, 2020","December 13, 2017",,"April 22, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States",14,,No Results Available,https://ClinicalTrials.gov/show/NCT03371329
NCT02677350,AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE),GALENE,Withdrawn,Crohn's Disease|Fistulizing Crohn's Disease|Stem Cells,Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs),"Evaluation of treatment emergent adverse events from the bone marrow-derived allogeneic mesenchymal stem cells implant|Clinically: to assess changes in the Crohn's Disease Activity Index (CDAI), the Perianal Disease Activity Index (PDAI).|Endoscopic assessment of rectum using a limited simplified endoscopic activity score for Crohn's disease (SES-CD) to evaluate extent and severity of ulcers.|Radiologic assessment using MRI|Evaluate symptomatic patients.|Evaluate the effect of local treatment with allogeneic bmMSCs using the short Inflammatory Bowel Disease Questionnaire (sIBDQ)|Evaluate the effect of local treatment with allogeneic bmMSCs using the Short Form (SF)-36 score|C-reactive protein (CRP)|Major Adverse Events",Joshua M Hare|University of Miami,All,"18 Years and older   (Adult, Older Adult)",Phase 1,0.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20150965,"December 1, 2019",December 2025,December 2026,"February 9, 2016",,"June 24, 2019","Univeristy of Miami Miller School of Medicine, Miami, Florida, United States",15,,No Results Available,https://ClinicalTrials.gov/show/NCT02677350
NCT01609283,A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis,,Completed,Amyotrophic Lateral Sclerosis,Biological: autologous mesenchymal stem cells,Number of patients with dose-limiting toxicities|Number of patients with adverse events|Change in serum sedimentation rate|Change in C-reactive protein levels|Change in complete blood counts|Change in total nucleated cell count in cerebrospinal fluid (CSF)|Change in protein level in cerebrospinal fluid (CSF)|Number of patients with presence of cancer cells in their cerebrospinal fluid (CSF),Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,27.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,11-008415,May 2012,"January 31, 2019","January 31, 2019","May 31, 2012",,"September 2, 2019","Mayo Clinic, Rochester, Minnesota, United States",16,,No Results Available,https://ClinicalTrials.gov/show/NCT01609283
NCT01983709,Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer,MSC,Terminated,Prostate Cancer,Biological: Allogeneic Human Mesenchymal Stem Cells,Amount of systemically infused (MSC) DNA relative to recipient DNA at sites of prostate cancer in men with localized adenocarcinoma of the prostate that are scheduled to undergo a prostatectomy|Feasibility of infusing MSCs into men with localized prostate cancer who plan to undergo a prostatectomy.|Determine the proportion of MSC to recipient DNA in the peripheral blood|Determine the proportion of MSC to recipient DNA within the seminal vesicle.|Changes in the Sexual Health Inventory for Men (SHIM) survey post-prostatectomy.|Change in urinary function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in bowel habits as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in sexual function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in hormonal function as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Change in overall satisfaction as assessed by the Expanded Prostate Cancer Index Composite (EPIC) survey post-prostatectomy|Safety as assessed by number of participants experiencing adverse events|Safety as assessed by number of participants experiencing serious adverse events|Safety as assessed by number of participants experiencing treatment-related adverse events,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Male,"18 Years to 100 Years   (Adult, Older Adult)",Phase 1,7.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,J1348|NA_00083720,October 2013,June 2017,June 2017,"November 14, 2013",,"July 16, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States",17,,No Results Available,https://ClinicalTrials.gov/show/NCT01983709
NCT02068794,MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer,,Recruiting,Malignant Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma,Other: Laboratory Biomarker Analysis|Procedure: Mesenchymal Stem Cell Transplantation|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter,"MTD, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I)|Number and severity of adverse events (Phase I)|Overall toxicity incidence (Phase I)|Proportion of patients alive and progression-free at 4 months (Phase II)|Toxicity profiles by dose level and patient (Phase I)|Maximum grade for each type of toxicity (Phase II)|Overall survival (Phase II)|Progression free survival (Phase II)|Tumor response defined as complete response or partial response (Phase II)",Mayo Clinic|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,54.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MC1266|NCI-2014-00016|P30CA015083,March 2014,"March 10, 2021","March 10, 2021","February 21, 2014",,"April 8, 2019","Mayo Clinic, Rochester, Minnesota, United States",18,,No Results Available,https://ClinicalTrials.gov/show/NCT02068794
NCT02675556,Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression,ANU,Terminated,Treatment Resistant Depression,Drug: Allo-hMSCs|Drug: Placebo,Incidence of any treatment-emergent serious adverse events (TE-SAEs)|Reduction of Inflammation,Joshua M Hare|University of Miami,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,1.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20140917,"October 31, 2017","March 26, 2019","March 26, 2019","February 5, 2016",,"April 1, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States",19,,No Results Available,https://ClinicalTrials.gov/show/NCT02675556
NCT04087889,Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer,,No longer available,Pancreatic Cancer,"Drug: Hope Biosciences Allogeneic, First Blood Relative Adipose-Derived Mesenchymal Stem Cells",,Hope Biosciences,Male,"Child, Adult, Older Adult",,,Industry,Expanded Access:Individual Patients,,Pancreatic Cancer,,,,"September 12, 2019",,"September 25, 2019","Hope Biosciences, Sugar Land, Texas, United States",20,,No Results Available,https://ClinicalTrials.gov/show/NCT04087889
NCT02808208,Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure,,Recruiting,End Stage Renal Disease (ESRD)|Vascular Access Complication,Biological: Adipose Derived Mesenchymal Stem Cells (AMSC),Hemodialysis outflow vein diameter|Hemodialysis AVF Blood flow,Mayo Clinic,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,44.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,15-009053,"June 7, 2017",July 2023,July 2023,"June 21, 2016",,"February 6, 2019","Mayo Clinic, Rochester, Minnesota, United States",21,,No Results Available,https://ClinicalTrials.gov/show/NCT02808208
NCT03265808,Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.,Alaunus,Recruiting,Major Depression|Alcohol Use Disorder,Drug: allogeneic human mesenchymal stem cells (allo-hMSCs)|Drug: Placebo,treatment emergent-serious adverse events|Reduction of Inflammation|Reduction in Depressive Symptoms|Reduction of alcohol use|Reduction in Anhedonia|Improvements in quality of life,Joshua M Hare|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Miami,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,80.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20170674|1R01AA024933-01A1,"March 18, 2018",February 2025,February 2026,"August 29, 2017",,"May 7, 2019","Interdisciplinary stem cell institute (ISCI), Miami, Florida, United States",22,,No Results Available,https://ClinicalTrials.gov/show/NCT03265808
NCT02625246,Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non‐Cystic Fibrosis Bronchiectasis,CELEB,Completed,Bronchiectasis,Biological: hMSCs,Number of Participant with treatment emergent serious adverse events|Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum|rate of decline of lung function|frequency of acute exacerbations|reported dyspnea and quality of life assessment|death from any cause,Marilyn Glassberg|University of Miami,All,"30 Years to 87 Years   (Adult, Older Adult)",Phase 1,6.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20150627,"February 4, 2016","May 15, 2019","May 15, 2019","December 9, 2015",,"August 27, 2019","University of Miami Hospitals & Clinics, Miami, Florida, United States",23,,No Results Available,https://ClinicalTrials.gov/show/NCT02625246
NCT04064879,The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine,,Suspended,"Chronic Migraine, Headache",Other: AD-SVF,Adverse Event Reporting|Headache Diary|Headache Impact Test (HIT-6),Neurological Associates of West Los Angeles|Cell Surgical Network Inc.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,10.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICSS-2018-014,"August 16, 2018","August 15, 2021","August 16, 2022","August 22, 2019",,"August 22, 2019","Neurological Associates of West Los Angeles, Santa Monica, California, United States",24,,No Results Available,https://ClinicalTrials.gov/show/NCT04064879
NCT03477942,Impact of Mesenchymal Stem Cells in Knee Osteoarthritis,,Recruiting,Musculoskeletal Pain|Knee Osteoarthritis|Cartilage Injury|Cartilage Degeneration,Biological: Autologous Mesenchymal Stem Cells,"Primary Endpoint: Incidence of treatment emergent major adverse events directly related to MSC injection|Secondary Endpoint: Development of Pain following injection based on Visual Analog Scale scoring.|Secondary Endpoint: Clinical Evaluation of Injection based on functional outcomes scoring using KOOS, IKDC and Lysholm scoring scales.|Secondary Endpoint: Reparative potential of intra-articular MSCs based on improvement in cartilage quality using MRI.",University Hospitals Cleveland Medical Center|Case Western Reserve University,All,18 Years to 60 Years   (Adult),Phase 1,16.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,JV 1.1,"October 1, 2018",October 2019,December 2019,"March 27, 2018",,"April 17, 2019","University Hospital Cleveland Medical Center, Cleveland, Ohio, United States",25,,No Results Available,https://ClinicalTrials.gov/show/NCT03477942
NCT02941666,Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip,,Recruiting,Osteonecrosis,,The quantity of mesenchymal stem cells present in the synovial fluid of patients with precollapse ON of the femoral head and postcollapse ON of the femoral head compared to patients without intraarticular hip pathology.,Mayo Clinic,All,"18 Years to 90 Years   (Adult, Older Adult)",,60.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,16-002241,September 2016,November 2021,November 2021,"October 21, 2016",,"March 7, 2019","Mayo Clinic, Rochester, Minnesota, United States",26,,No Results Available,https://ClinicalTrials.gov/show/NCT02941666
NCT00813969,Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS,,Completed,Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis,Biological: Autologous mesenchymal stem cell transplantation,"To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS|To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions|To evaluate safety and tolerability of autologous MSC transplantation over 6 months",The Cleveland Clinic|University Hospitals Cleveland Medical Center,All,18 Years to 55 Years   (Adult),Phase 1,24.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MS-MSC-001,March 2011,January 2014,May 2014,"December 23, 2008",,"March 30, 2016","Cleveland Clinic Mellen Center, Cleveland, Ohio, United States",27,,No Results Available,https://ClinicalTrials.gov/show/NCT00813969
NCT03308565,Adipose Stem Cells for Traumatic Spinal Cord Injury,CELLTOP,Recruiting,Spinal Cord Injuries|Paralysis,"Biological: Autologous, Adipose derived Mesenchymal Stem Cells",Incidence of acute adverse events|Incidence of delayed adverse events|Severity of adverse events|Relationship of adverse events to study drug|Incidence of serious adverse events (SAE)|Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by motor evoked potentials (MEP)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide,Allan Dietz|Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,10.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-004621,"December 5, 2017",November 2022,November 2023,"October 12, 2017",,"March 7, 2019","Mayo Clinic, Rochester, Minnesota, United States",28,,No Results Available,https://ClinicalTrials.gov/show/NCT03308565
NCT01142856,Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS),,Completed,Amyotrophic Lateral Sclerosis,Biological: autologous mesenchymal stem cells,Safety|Neurologic disability score,Mayo Clinic,All,"18 Years and older   (Adult, Older Adult)",Phase 1,1.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09-001995,June 2010,April 2011,April 2011,"June 11, 2010",,"May 3, 2012","Mayo Clinic, Rochester, Minnesota, United States",29,,No Results Available,https://ClinicalTrials.gov/show/NCT01142856
NCT03691909,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis,HB-adMSCs,"Active, not recruiting",Rheumatoid Arthritis,Drug: HB-adMSC,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|The effect of single inject of HB-adMSCs on TNF-a in patients with acute RA|The effect of single inject of HB-adMSCs on IL-6 in patients with acute RA|The effect of single inject of HB-adMSCs on CRP in patients with acute RA|The effect of single inject of HB-adMSCs on ESR in patients with acute RA|The effect of single inject of HB-adMSCs on joint count in patients with acute RA.,Hope Biosciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,15.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Rheumatoid Arthritis,"September 25, 2018","February 1, 2020","March 1, 2020","October 2, 2018",,"August 26, 2019","Accurate Clinical Research, Pasadena, Texas, United States",30,,No Results Available,https://ClinicalTrials.gov/show/NCT03691909
NCT02408432,Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines,,Recruiting,Cardiomyopathy|Heart Failure,Biological: Mesenchymal Stem Cell Transplantation|Drug: Standard of Care for Heart Failure,Adverse Events of Allogeneic Human Mesenchymal Stem Cells (hMSCs) Determined by CTCAE version 4|Change in Left Ventricular Ejection Fraction (LVEF),M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,45.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2014-0519|NCI-2015-00969|P30CA016672,"January 11, 2016","January 31, 2023","January 31, 2023","April 3, 2015",,"August 22, 2019","M D Anderson Cancer Center, Houston, Texas, United States",31,,No Results Available,https://ClinicalTrials.gov/show/NCT02408432
NCT03171194,Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus,,Completed,System; Lupus Erythematosus,Drug: Low Dose Mesenchymal Stem Cells (MSCs),Frequency of Grade 3 or higher adverse events|Frequency of All Adverse Events|Change in Disease Activity|Change in Patient Reported Outcomes - Life|Change in Patient Reported Outcomes - Fatigue|Change in Patient Reported Outcomes - Pain|Change in Patient Reported Outcomes - Depression|Change in Disease Biomarkers - Cellular|Change in Disease Biomarkers - Serum,Medical University of South Carolina,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,00061632,"April 27, 2017","April 30, 2018","October 25, 2018","May 31, 2017",,"May 2, 2019","Emory University, Atlanta, Georgia, United States|Medical University of South Carolina, Charleston, South Carolina, United States",32,,No Results Available,https://ClinicalTrials.gov/show/NCT03171194
NCT01668576,Properties of Mesenchymal Stem Cells in Lung Transplant,,Terminated,Lung Transplantation,,Intrinsic variability of MSCs measured by time to third passage of confluent MSC|2-3 IDO production measured as ug/mL of passage 3 MSCs|Percent specific inhibition of CD4 and CD8 T cell proliferation toward donor target cells in one way mixed-lymphocyte reactions,Emory University,All,"18 Years to 70 Years   (Adult, Older Adult)",,4.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,IRB00053075,August 2012,September 2014,September 2014,"August 20, 2012",,"January 14, 2016","Emory University, Atlanta, Georgia, United States",33,,No Results Available,https://ClinicalTrials.gov/show/NCT01668576
NCT02833792,Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease,,Recruiting,Alzheimer Dementia,Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Other: Placebo,Safety of aMBMC administration|Efficacy of aMBMC administration,"Stemedica Cell Technologies, Inc.|Stemedica International SA",All,"55 Years to 80 Years   (Adult, Older Adult)",Phase 2,40.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,STEM105-M-AD,June 2016,December 2019,June 2020,"July 14, 2016",,"April 9, 2019","John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States",34,,No Results Available,https://ClinicalTrials.gov/show/NCT02833792
NCT02611167,Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease,,"Active, not recruiting",Parkinson's Disease,Biological: Allogeneic bone marrow-derived MSCs,Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy|Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score|Change in motor function as assessed by the UPDRS Motor score|Change in motor function as assessed by Timed-Up-and-Go (TUG)|Change in disability as measured by the Modified Hoehn and Yahr Scale|functional connectivity between substantia nigra and dorsal striatum as assessed by resting state functional magnetic resonance imaging (fMRI)|perfusion as assessed by arterial spin-labeled (ASL) perfusion MRI|structural connectivity as assessed by diffusion-weighted MRI for diffusion tensor image (DTI) analysis|volume of subcortical structures as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|cortical thickness as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in gross brain structure as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in brain activity as assessed by task state fMRI|Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score|Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)|Change in cognitive function as assessed by the Montreal Cognitive Assessment (MoCA)|Change in immunologic response as assessed by plasma concentrations of cytokines|Change in suicidal ideation or behaviors as assessed by and Columbia Suicide Severity Rating Scale (CSSRS),"The University of Texas Health Science Center, Houston",All,"45 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC-MS-Schiess MSC PD,"November 1, 2017",November 2019,November 2019,"November 20, 2015",,"November 7, 2018","The University of Texas Health Science Center at Houston, Houston, Texas, United States",35,,No Results Available,https://ClinicalTrials.gov/show/NCT02611167
NCT03692221,Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease,,Not yet recruiting,Disc Degeneration,Drug: MSC Treatment group 1 (low dose)|Drug: MSC Treatment group 2 (high dose)|Other: Healthy Control (no treatment),Rate of treatment related adverse events|Changes in Pain -Visual Analogue Scale (VAS) for back pain|Changes in Pain - Oswestry Disability Index (ODI) scores over time|changes in Quality of life - Short form Health Survey 36 (SF-36)|changes in MRI monitoring of transplant site,Salim M Hayek|University Hospitals Cleveland Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Early Phase 1,24.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,014924/0012/A002,June 2019,"September 30, 2021","September 30, 2022","October 2, 2018",,"April 4, 2019","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",36,,No Results Available,https://ClinicalTrials.gov/show/NCT03692221
NCT02065245,AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery.,CRATUS,"Active, not recruiting",Aging Frailty,Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Biological: Placebo,Incidence of any treatment emergent-serious adverse events|Difference in rate of decline of Frailty|Difference in subject quality of life assessment(s):|Death from any cause|Exercise change in ejection fraction.|Inflammatory Markers.,"Joshua M Hare|The Emmes Company, LLC|University of Miami",All,"60 Years to 95 Years   (Adult, Older Adult)",Phase 1|Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20130646,"March 3, 2014",December 2020,December 2020,"February 17, 2014",,"June 24, 2019","ISCI/University of Miami Miller School of Medicine, Miami, Florida, United States",37,,No Results Available,https://ClinicalTrials.gov/show/NCT02065245
NCT01162915,Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury,,Suspended,Spinal Cord Injury,Biological: Autologous bone marrow-derived mesenchymal stem cells.,Safety,TCA Cellular Therapy,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,10.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2009-SCI-I,July 2010,May 2014,May 2014,"July 15, 2010",,"May 9, 2014","TCA Cellular Therapy, LLC, Covington, Louisiana, United States",38,,No Results Available,https://ClinicalTrials.gov/show/NCT01162915
NCT04061746,Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells,,Recruiting,"Diabetes Mellitus, Type 1",Biological: Mesenchymal Stem Cells (MSCs)|Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin),12 month Change in C-peptide area under the curve after a 2-hour MMTT|6 Month Change in C-Peptide area under the curve after a 2-hour MMTT|6 Month peak C-peptide after a 2-hour MMTT|1 year peak C-peptide after a 2-hour MMTT|Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements,Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"12 Years to 30 Years   (Child, Adult)",Phase 1,50.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00085542|R01DK118529-01A1,"November 1, 2019","July 1, 2023","July 1, 2023","August 20, 2019",,"October 11, 2019","Medical University of South Carolina, Charleston, South Carolina, United States",39,,No Results Available,https://ClinicalTrials.gov/show/NCT04061746
NCT02685098,A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation,CHAMP,Recruiting,Ischemia|Peripheral Arterial Disease|Peripheral Vascular Disease|Vascular Disease|Arterial Occlusive Disease|Arteriosclerosis|Atherosclerosis|Cardiovascular Disease|Pathologic Processes|Orthopedic Procedures|Amputation,Biological: Allogeneic bone marrow derived mesenchymal stem cells,"Number of participants with treatment-related adverse events occurring during the enrollment period as assessed by the Investigator using the MeDRA scale.|Gene and protein arrays, IHC staining, and multiparametric flow cytometry will measure the time period of retention of allogeneic MSCs in harvested human skeletal muscle tissue post-MSC implantation.|Recruitment of proangiogenic hematopoietic cells into sites of ischemia will be measured and reported as assessed by the role of MSCs injected in human skeletal muscle at the time of amputation.",Indiana University,All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 1,16.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,1505714405,January 2017,September 2021,September 2025,"February 18, 2016",,"February 11, 2019","Indiana University, Indianapolis, Indiana, United States",40,,No Results Available,https://ClinicalTrials.gov/show/NCT02685098
NCT01751282,Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds,,Terminated,Non Healing Wounds,Genetic: Stem Cell,Wound closure|Overall rate of wound healing reduction,Roger Williams Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RO1AR06034201A1,June 2010,June 2015,June 2015,"December 17, 2012",,"October 4, 2016","Roger Williams Medical Center, Providence, Rhode Island, United States",41,,No Results Available,https://ClinicalTrials.gov/show/NCT01751282
NCT04064983,Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease,,No longer available,Parkinson Disease,Drug: HB-adMSC,,Hope Biosciences,All,"18 Years and older   (Adult, Older Adult)",,,Industry,Expanded Access:Individual Patients,,Parkinson's disease,,,,"August 22, 2019",,"September 25, 2019","Clinical Trial Network, Houston, Texas, United States",42,,No Results Available,https://ClinicalTrials.gov/show/NCT04064983
NCT04064957,Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Spinal Cord Injury,,No longer available,Spinal Cord Injuries,Drug: HB-adMSCs,,Hope Biosciences,All,"18 Years and older   (Adult, Older Adult)",,,Industry,Expanded Access:Individual Patients,,Chronic Spinal Cord Injury,,,,"August 22, 2019",,"September 25, 2019","Clinical Trial Network, Houston, Texas, United States",43,,No Results Available,https://ClinicalTrials.gov/show/NCT04064957
NCT00587990,Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS),PROMETHEUS,Terminated,"Stem Cell Transplantation|Ventricular Dysfunction, Left",Biological: Lower dose mesenchymal stem cell (MSC) injection|Genetic: Placebo|Biological: Higher dose MSC injection,Number of Patients With Serious Adverse Events|Change in Infarct Scar Size (ISS) Over 18 Month Period|Left Ventricular Function (LVF) in Region of MSC Injection|Regional Left Ventricular Wall Thickening|Left Ventricular End Diastolic Wall Thickness|Change in Left Ventricular End Diastolic and Systolic Volume|Change in Left Ventricular Ejection Fraction|Change in Peak Volume Oxygen|Change in Six Minute Walk Test|Change in NYHA Functional Class|Minnesota Living With Heart Failure Questionnaire Scores|Incidence of Major Adverse Cardiac Events (MACE)|Number of Participants With Abnormal 48-Hour Ambulatory ECG Recordings|Change in Pulmonary Function|Serial Troponin Values (ng/mL)|Creatinine Kinase - Muscle/Brain (MB) (ng/mL)|Number of Clinically Significant Laboratory Values|Rate of Treatment Emergent Adverse Events|Number of Abnormal Echocardiogram Readings 2 Days Post CABG.,"Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|Johns Hopkins University Specialized Center for Cell Based Therapy|The Emmes Company, LLC|University of Miami",All,"21 Years to 80 Years   (Adult, Older Adult)",Phase 1|Phase 2,9.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20070598|U54HL081028,November 2007,June 2011,June 2011,"January 8, 2008","April 2, 2015","September 10, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",44,,Has Results,https://ClinicalTrials.gov/show/NCT00587990
NCT02395029,Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD,PMD-MSC-PD-01,Completed,Peyronie's Disease,Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs),Peak Systolic Velocity without trimix (cm/s)|End Diastolic Velocity without trimix (cm/s),Melissa Marchand|Z Urology,Male,"18 Years and older   (Adult, Older Adult)",Phase 1,5.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMD-MSC-PD-01,August 2013,December 2014,March 2015,"March 20, 2015",,"March 20, 2015","Z Urology, Coral Springs, Florida, United States",45,,No Results Available,https://ClinicalTrials.gov/show/NCT02395029
NCT02398370,Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED,PMD-MSC-ED-01,Completed,Erectile Dysfunction,Biological: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs),Peak Systolic Velocity without trimix (cm/s)|End Diastolic Velocity without trimix (cm/s),Melissa Marchand|Z Urology,Male,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1,8.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMD-MSC-ED-01,July 2013,December 2014,March 2015,"March 25, 2015",,"April 27, 2015","Z Urology, Coral Springs, Florida, United States",46,,No Results Available,https://ClinicalTrials.gov/show/NCT02398370
NCT03355365,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,,Recruiting,Multiple Sclerosis,Biological: Intrathecal MSC-NP injection|Other: Intrathecal saline injection,Expanded Disability Status Scale (EDSS) Plus|Multiple sclerosis functional composite (MSFC)|Bladder function,Tisch Multiple Sclerosis Research Center of New York,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TISCHMS-MSCNP-002,"September 21, 2018",November 2020,November 2023,"November 28, 2017",,"May 31, 2019","Tisch MS Research Center of New York, New York, New York, United States",47,,No Results Available,https://ClinicalTrials.gov/show/NCT03355365
NCT02529566,Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine,,Unknown status,Lumbar Degenerative Disc Disease|Lower Back Pain|Chronic Lower Back Pain,,Numeric Pain Rating Scale (NPRS)|Oswestry Disability Index (ODI)|SF-12 Health Survey|EQ-5D Quality Adjusted Life Years,"The Foundation for Spinal Research, Education and Humanitarian Care, Inc.",All,"18 Years to 85 Years   (Adult, Older Adult)",,100.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,HSC-2013,July 2013,July 2018,July 2018,"August 20, 2015",,"February 15, 2017","Trinity Stem Cell Institution, Odessa, Florida, United States",48,,No Results Available,https://ClinicalTrials.gov/show/NCT02529566
NCT02013700,Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER),AETHER,Completed,Idiopathic Pulmonary Fibrosis (IPF),Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|Biological: matched placebo,To determine the safety and tolerability of intravenous allo hMSCs in patients with Idiopathic Pulmonary Fibrosis (IPF).|- To explore effects of allo hMSCs on lung function: forced vital capacity (FVC).|To explore effects of allogenic human mesenchymal stem cells on symptom related quality of life.|Difference in frequency of acute exacerbations of Idiopathic Pulmonary Fibrosis (IPF)|Death from any cause.|To explore effects of allogenic human mesenchymal stem cells on lung function: Diffusing Capacity (DLCO),"Joshua M Hare|The Lester And Sue Smith Foundation|The Emmes Company, LLC|University of Miami",All,"40 Years to 90 Years   (Adult, Older Adult)",Phase 1,9.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20120946,"November 13, 2013","December 11, 2015","November 24, 2016","December 17, 2013",,"March 6, 2019","Interdisciplinary Stem Cell Institute / University of Miami, Miami, Florida, United States",49,,No Results Available,https://ClinicalTrials.gov/show/NCT02013700
NCT01933802,Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis,,Completed,Multiple Sclerosis,Biological: intrathecal administration of autologous MSC-NP,Number of participants with adverse events|Number of participants with adverse events .|Preliminary evaluation of efficacy,Tisch Multiple Sclerosis Research Center of New York,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TISCHMS-MSCNP-001|IND 13889,April 2014,December 2016,March 2017,"September 2, 2013",,"March 19, 2018","Tisch MS Research Center of New York, New York, New York, United States",50,,No Results Available,https://ClinicalTrials.gov/show/NCT01933802
NCT02557724,Mobilization of Mesenchymal Stem Cells During Liver Transplantation,,Completed,Liver Failure|Liver Neoplasm,Procedure: blood samples,post operative liver injury|Total Bilirubin level|(INR) International Normalized Ratio|(ALT) Alanine Aminotransferase|(AST) Aspartate Aminotransferase,"Rutgers, The State University of New Jersey",All,"18 Years to 80 Years   (Adult, Older Adult)",,35.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,20140000266,September 2015,July 2017,July 2017,"September 23, 2015",,"October 16, 2018","University Hospital, Newark, New Jersey, United States",51,,No Results Available,https://ClinicalTrials.gov/show/NCT02557724
NCT00851162,Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions,,Withdrawn,Bone Neoplasms,Biological: Trinity multipotent stem cells|Biological: Demineralized bone matrix(DBM),Time to fill bony defect|Adverse reaction from bone graft,Emory University,All,"11 Years and older   (Child, Adult, Older Adult)",Phase 2|Phase 3,0.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB00009762,March 2009,March 2010,March 2010,"February 25, 2009",,"November 28, 2012","Emory University, Atlanta, Georgia, United States",52,,No Results Available,https://ClinicalTrials.gov/show/NCT00851162
NCT01840540,MSC for Occlusive Disease of the Kidney,,Completed,Atherosclerotic Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Hypertension,Drug: Arterial infusion of autologous mesenchymal stem cells,Renal blood flow and function in the treated kidneys.|Level of kidney function.,Mayo Clinic,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,6.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-009298,April 2013,March 2014,April 2017,"April 25, 2013",,"August 7, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",53,,No Results Available,https://ClinicalTrials.gov/show/NCT01840540
NCT04029896,Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy,,No longer available,Cerebral Palsy,Drug: HB-adMSC,,Hope Biosciences,Male,"3 Years and older   (Child, Adult, Older Adult)",,,Industry,Expanded Access:Individual Patients,,Cerebral Palsy,,,,"July 23, 2019",,"September 25, 2019","Clinical Trial Network, Houston, Texas, United States",54,,No Results Available,https://ClinicalTrials.gov/show/NCT04029896
NCT03337243,Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis,,"Active, not recruiting",Knee Osteoarthritis|Knee Pain Chronic|Joint Disease|Arthritis|Osteo Arthritis Knee|Musculoskeletal Disease,Procedure: HAM and HUMCWJ Injections,Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months|Change in pain during sit-to-stand over 3 months|Change in pain during supine to upright over 3 months|Change in pain during ascent/decent stairs over 3 months,Sport and Spine Rehab Clinical Research Foundation,All,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,60.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,StemCell,"May 1, 2017","April 1, 2019","May 1, 2019","November 8, 2017",,"March 25, 2019","Scott Medical Health Center, Pittsburgh, Pennsylvania, United States",55,,No Results Available,https://ClinicalTrials.gov/show/NCT03337243
NCT02398604,Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome,ELPIS,Terminated,Hypoplastic Left Heart Syndrome,Drug: Allo-hMSCs|Drug: Placebo,"Monitor major adverse cardiac events|Composite Change from baseline in right ventricular function, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular end-systolic diameter and tricuspid regurgitation|Number of participants with incidence of mortality or need for transplantation after the BDCPA operation|Composite Changes in somatic growth velocity over time (weight, height, head circumference) from the BDCPA operation|Assessment of Co-morbidity","Joshua M Hare|University of Maryland, College Park|University of Miami",All,up to 30 Days   (Child),Phase 1,5.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20140718,April 2015,March 2019,March 2019,"March 25, 2015",,"June 25, 2019","University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",56,,No Results Available,https://ClinicalTrials.gov/show/NCT02398604
NCT03058068,Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis,HAPI,Not yet recruiting,Cystic Fibrosis,Biological: Allo-hMSCs|Biological: Placebo,Incidence of any treatment-emergent serious adverse event (TE-SAE)|Change in Symptoms for pulmonary function test|Change in Symptoms 6-minute walk test|Change in Symptoms of body mass index|Change in Rate of pulmonary exacerbations|Change in Local and Systemic Inflammation in inflammatory markers|Change in Local and Systemic Inflammation for sputum inflammatory markers|Change in Local and Systemic Inflammation related to quality of life|Change in Local and Systemic Inflammation via the short form-36|Change in Local and Systemic Inflammation via the PHQ-9 Questionnaire|Change in Local and Systemic Inflammation via the CFQ-R Questionnaire|Change in Local and Systemic Inflammation via the GAD-7 Questionnaire,Joshua M Hare|University of Miami,All,20 Years to 45 Years   (Adult),Phase 1,18.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20160140,December 2019,September 2027,September 2028,"February 20, 2017",,"June 24, 2019","ISCI / University of Miami Miller School of Medicine, Miami, Florida, United States",57,,No Results Available,https://ClinicalTrials.gov/show/NCT03058068
NCT04063215,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy,,Not yet recruiting,Traumatic Brain Injury,Drug: HB-adMSC,Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basos|Absolute Neutrophils|Absolute Lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature Granulocytes|Absolute Immature Granulocytes|Platelets|Prothrombin Time|INR|Urine Pregnancy|Whole brain MRI|PET/DT-MRI|Glasgow Outcome Score|Galveston Orientation and Amnesia Test|Rivermead Post-Concussion Symptoms Questionnaire|Automated Neuropsychological Assessment Metrics|Verbal Selective Reminding Test|Verbal Fluency Test|Stroop|Interleukin 1-alpha|Interleukin 4|Tumor necrosis factor alpha|Interleukin 6|Interleukin 10,"Hope Biosciences|The University of Texas Health Science Center, Houston",All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,24.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Neurologic Injury,"October 30, 2019","August 29, 2020","August 29, 2020","August 21, 2019",,"September 25, 2019","Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston, Texas, United States",58,,No Results Available,https://ClinicalTrials.gov/show/NCT04063215
NCT02331134,Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer,,Recruiting,Malignant Melanoma|Head and Neck Cancer,Drug: Filgrastim,Tissue and Hematopoietic Stem Cell Collection|Identify pharmacodynamic markers,"University of Colorado, Denver|Karsh Family Research Fund",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,14-0842.cc,"May 13, 2015",March 2020,March 2020,"January 6, 2015",,"December 3, 2018","University of Colorado Cancer Center, Aurora, Colorado, United States",59,,No Results Available,https://ClinicalTrials.gov/show/NCT02331134
NCT03137199,Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma,ASTEC,Recruiting,Asthma,Biological: hMSCs,Number of Participant with treatment emergent serious adverse events|Difference in lung function|Decrease in peripheral eosinophilia|Difference in subject reported dyspnea and quality of life assessments|Death from any cause,Marilyn Glassberg|University of Miami,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,6.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20160350,"June 22, 2017",November 2020,May 2021,"May 2, 2017",,"May 20, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States",60,,No Results Available,https://ClinicalTrials.gov/show/NCT03137199
NCT02379442,Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids,,Terminated,Graft-Versus-Host Disease,Biological: MSC,Proportion of Subjects Without a Treatment Related Severe Adverse Event,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",All,"4 Years to 99 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,1.0,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,150088|15-H-0088,"February 23, 2015","December 13, 2017","December 13, 2017","March 5, 2015","May 1, 2019","May 1, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",61,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02379442/Prot_SAP_000.pdf",Has Results,https://ClinicalTrials.gov/show/NCT02379442
NCT03014037,Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration,,"Active, not recruiting",Osteoarthritis,Procedure: Unilateral Bone Marrow Procurement|Procedure: Bilateral Bone Marrow Procurement,Change Quality of Life assessed by the Emory Quality of Life (EQOL) Survey Score|Change in the Knee Injury and Osteoarthritis Outcome Score (KOOS)|Capacity of Isolated Cells to Differentiate Down Cell Lineages,Emory University,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,35.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,IRB00093044,"September 7, 2017",May 2021,May 2021,"January 9, 2017",,"July 10, 2019","The Emory Clinic, Atlanta, Georgia, United States",62,,No Results Available,https://ClinicalTrials.gov/show/NCT03014037
NCT02013674,The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study),Trident,Unknown status,Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction,Biological: Allogeneic hMSCs,Treatment-emergent serious adverse events (SAE).|Computed Tomography (CT) derived measures of left ventricular function.|Tissue perfusion measured by Computed Tomography (CT).|Peak Oxygen Consumption (VO2) (by treadmill determination).|Six-minute walk test.|New York Heart Association functional class.|Major Adverse Cardiac Events (MACE)|Secondary safety endpoints.|Minnesota Living with Heart Failure (MLHF)Questionnaire|Echocardiographic-derived measures of left ventricular function,"Joshua M Hare|The Emmes Company, LLC|University of Miami",All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 2,30.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20120660,November 2013,"March 2, 2017",June 2019,"December 17, 2013",,"September 14, 2017","ISCI / University of Miami, Miami, Florida, United States",63,,No Results Available,https://ClinicalTrials.gov/show/NCT02013674
NCT02266394,Hypoxia and Inflammatory Injury in Human Renovascular Hypertension,,"Active, not recruiting",Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Disease|Chronic Kidney Disease,Drug: Mesenchymal stem cell|Procedure: Mesenchymal stem cell delivery with stent placement,Change in Kidney function|Safety of Mesenchymal stem cell infusion|Decrease in Kidney inflammation,Mayo Clinic|University of Mississippi Medical Center|University of Alabama at Birmingham,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 1,42.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14-002799,October 2014,March 2020,March 2020,"October 17, 2014",,"June 14, 2019","University of Alabama, Birmingham, Alabama, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi, Jackson, Mississippi, United States",64,,No Results Available,https://ClinicalTrials.gov/show/NCT02266394
NCT03822858,Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis,,Available,Multiple Sclerosis,Drug: Intrathecal MSC-NP injection,,Tisch Multiple Sclerosis Research Center of New York,All,"18 Years to 70 Years   (Adult, Older Adult)",,,Other,Expanded Access:Treatment IND/Protocol,,TISCHMS-MSCNP-003,,,,"January 30, 2019",,"September 10, 2019","Tisch MS Research Center of New York, New York, New York, United States",65,,No Results Available,https://ClinicalTrials.gov/show/NCT03822858
NCT03059355,Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.,CERES,Recruiting,Endothelial Dysfunction|Metabolic Syndrome|Chronic Inflammation,Biological: UCMSCs|Biological: BMMSCs|Other: Placebo,Incidence of any treatment-emergent serious adverse events (TE-SAEs)|Change of inflammatory markers|Effect on Frailty Phenotype Score|Effect on Physical Performance through Quality of Life questionnaires|Change of Pro-inflammatory cytokines in laboratory analysis|Determine if there is an improvement in symptoms between subjects receiving umbilical cord cells versus bone marrow cells|Number of study participants experiencing safety events (difference between dose and placebo subjects),Joshua M Hare|University of Miami,All,"21 Years to 95 Years   (Adult, Older Adult)",Phase 1|Phase 2,37.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20170095,"April 12, 2018",June 2025,June 2026,"February 23, 2017",,"August 6, 2019","ISCI / University of Miami Miller School of Medicine, Miami, Florida, United States",66,,No Results Available,https://ClinicalTrials.gov/show/NCT03059355
NCT03522545,Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression,,Not yet recruiting,Treatment-resistant Bipolar Depression,Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Biological: Placebo,"Change in depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in Functional impairment as assessed by the Functioning Assessment Short Test (FAST)|Change in Overall functioning in living as assessed by the Global Assessment of Functioning (GAF)|Change in Clinical Global Impression Scale for Bipolar lllness (CGI-BP), severity of mania subscale|Change in Clinical Global Impression Scale for Bipolar lllness (CGI-BP), severity of depression subscale|Change in Clinical Global Impression Scale for Bipolar lllness (CGI-BP), severity overall subscale|Change in neurocognition as assessed by the California Verbal Learning Test|Change in problem-solving ability as assessed by the Wisconsin Card Sorting Test (WCST)|Number of participants with inflammatory markers as assessed by multiplex biomarker analysis|Change in brain-derived neurotrophic factor (BDNF) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Change in C-reactive protein (CRP) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Number of participants with a change in brain activity between baseline and week 26 as assessed by Magnetic Resonance Imaging (MRI)|Number of participants who withdrawal due to Adverse Events (AEs)|Number of participants with suicidal ideation based on clinical assessment|Number of participants with treatment emergent mania or hypomania as assessed by the Young Mania Rating Scale (YMRS) and clinical assessment","The University of Texas Health Science Center, Houston",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-MS-16-0657,"June 1, 2018","June 1, 2020","June 1, 2020","May 11, 2018",,"May 11, 2018","The University of Texas Health Science Center at Houston, Houston, Texas, United States",67,,No Results Available,https://ClinicalTrials.gov/show/NCT03522545
NCT02848131,Senescence in Chronic Kidney Disease,,"Active, not recruiting",Chronic Kidney Disease,Drug: Group 2: Dasatinib|Drug: Group 2: Quercetin,Change in Number of Senescent Cells|Change in Proportion of Senescent Mesenchymal Stem Cells Present|Change in Mesenchymal Stem Cell Function|Change in Frailty Index Score|Change in Kidney Function,Mayo Clinic,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,16.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-005843,July 2016,"June 2, 2019","June 2, 2020","July 28, 2016","June 26, 2019","June 26, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",68,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02848131/Prot_SAP_000.pdf",Has Results,https://ClinicalTrials.gov/show/NCT02848131
NCT02442817,Linagliptin and Mesenchymal Stem Cells: A Pilot Study,,Unknown status,Schizophrenia,Drug: Linagliptin,SDF1-α (stromal cell-derived factor alpha) Concentration|DPP-4 (Dipeptidyl peptidase-4) Activity|Monocyte State|Absolute/Differential leukocyte count|CD271+ cells,"University of Nevada, Reno|Augusta University",All,18 Years to 45 Years   (Adult),Phase 4,18.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,LING-1,April 2015,April 2017,May 2017,"May 13, 2015",,"May 20, 2016","University of Nevada School of Medicine, Reno, Nevada, United States",69,,No Results Available,https://ClinicalTrials.gov/show/NCT02442817
NCT00498316,Cord Blood Expansion on Mesenchymal Stem Cells,,Completed,Myelodysplastic Syndrome|Leukemia,Procedure: Cord Blood Infusion|Drug: Busulfan|Drug: Fludarabine|Drug: Rituximab|Other: ATG|Drug: Cyclophosphamide|Drug: Clofarabine|Radiation: Total Body Irradiation (TBI)|Drug: Melphalan|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: G-CSF,Engraftment and Time to Engraftment,M.D. Anderson Cancer Center|ViaCell|National Institutes of Health (NIH)|National Cancer Institute (NCI),All,"1 Year to 80 Years   (Child, Adult, Older Adult)",Phase 1,98.0,Other|Industry|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2005-0781|NCI-2011-02823|RP100469 02|1P01CA148600-01A1|5R01CA061508-20,July 2007,October 2016,October 2016,"July 10, 2007",,"October 31, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",70,,No Results Available,https://ClinicalTrials.gov/show/NCT00498316
NCT02381366,Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study,,Completed,Bronchopulmonary Dysplasia,Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells,Number of participants with adverse reactions for 84 days after treatment|Number of participants with adverse reactions between 84 days after treatment and 20 months of corrected age|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)|Hospital Re-admission between 84 days after treatment until 20 months of corrected age|Bayley Scales of Infant and Toddler Development between 84 days after treatment until 20 months of corrected age,Medipost America Inc.|Medipost Co Ltd.,All,up to 14 Days   (Child),Phase 1|Phase 2,12.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MD-BPD-US001,March 2015,September 2016,May 2018,"March 6, 2015",,"August 16, 2018","Rush University Medical Center, Chicago, Illinois, United States",71,,No Results Available,https://ClinicalTrials.gov/show/NCT02381366
NCT03925324,Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device,STEM-VAD,Recruiting,Ischemic Heart Disease|Non-ischemic Cardiomyopathy,Biological: Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Other: Placebo,Temperature|Uncontrolled systemic infection|All-cause mortality|NK cell depletion|Change in the following cardiac biomarker|Change in RV systolic function|Hospitalizations due to right heart failure|6 minute walk distance changes|Gout flares,Rebecca Torguson|Medstar Health Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STEMVAD-001,"May 3, 2019",May 2021,June 2021,"April 24, 2019",,"August 5, 2019","MedStar Washington Hospital Center, Washington, District of Columbia, United States",72,,No Results Available,https://ClinicalTrials.gov/show/NCT03925324
NCT04040348,Alzheimer's Disease Stem Cells Multiple Infusions,,Recruiting,Alzheimer Disease,Biological: 100 million cells allogeneic hMSC|Biological: 200 million cells allogeneic hMSC,Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs)|Cognitive function over time as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog 11)|Cognitive function over time as assessed by the Mini Mental State Examination (MMSE) of Folstein test|Depressive symptoms over time as assessed by the Geriatric Depression Scale (GDS) Short Version|Olfactory function over time as assessed by the Odor Identification test.|Participant quality of life over time assessed via Alzheimer's Disease Related Quality of Life (ADRQL-40) Questionnaire as completed by the caregiver|Participant quality of life over time as assessed via the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Questionnaire as completed by the caregiver|Neuropsychiatric Inventory-Q (NPI-Q) Scores over time|Caregiver's Quality of life over time as assessed by the Caregiver Self-Assessment Questionnaire scores|Biomarker levels over time|Serum ApoE level over time|Serum PRA level over time|Serum Tau protein level over time|Cerebrospinal Fluid (CSF) Biomarker levels over time|CSF ApoE level over time|CSF PRA level over time|CSF Tau protein level over time|Change in hippocampal volume,Bernard (Barry) Baumel|University of Miami,All,"50 Years to 85 Years   (Adult, Older Adult)",Phase 1,10.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,20190438,"September 16, 2019","September 1, 2021","September 1, 2021","July 31, 2019",,"September 17, 2019","University of Miami, Miami, Florida, United States",73,,No Results Available,https://ClinicalTrials.gov/show/NCT04040348
NCT03158896,Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease,,Recruiting,Acute Graft Versus Host Disease,Biological: MSCTC-0010 Dose Escalation,proportion of participants who have a TRSAE after infusion of MSCTC 0010|Proportion of participants who achieve a complete response (CR) of aGVHD by study day 42|Proportion of participants with improvement of GVHD in 1 or more organs involved with GVHD by day 42|Occurrence of addition of escalated immunosuppressive therapy by day 90|Occurrence of Formation of ectopic tissue foci at day 90,University of Kansas Medical Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,10.0,Other,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIT-2016-aGvHD-MSCTC-0010,"July 9, 2018",August 2020,August 2020,"May 18, 2017",,"August 28, 2019","Kansas University Cancer Center, Kansas City, Kansas, United States",74,,No Results Available,https://ClinicalTrials.gov/show/NCT03158896
NCT01087996,The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study),,Completed,Stem Cell Transplantation,Biological: Auto-hMSCs|Biological: Allo-hMSCs,"Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month|CT Measure of Left Ventricular Ejection Fraction|CT Measure of End Diastolic Volume|CT Measure of End Systolic Volume|CT Measure of Scar Size as % of LV Mass|Change in Distance Walked in 6-minutes From Baseline.|Change in Minnesota Living With Heart Failure Total Score|Change in New York Heart Association Class at 12-months","University of Miami|National Heart, Lung, and Blood Institute (NHLBI)|The Emmes Company, LLC",All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,31.0,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20090352|R01HL110737|R01HL107110|R01HL084275|P20HL101443|R01HL094849,March 2010,April 2011,October 2012,"March 16, 2010","May 27, 2015","May 27, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States",75,,Has Results,https://ClinicalTrials.gov/show/NCT01087996
NCT03909139,BMAC Use With Labral Repair,,Recruiting,Acetabular Labrum Tear|Pincer Lesion|Femoro Acetabular Impingement|Chondral Defect|Bone Marrow Aspirate Concentrate|Mesenchymal Stem Cell,Biological: BMAC,Change in mHHS Surveys from preoperative to various postoperative timepoints|Progression of arthritis|Change HOS Surveys from preoperative to various postoperative timepoints|Change NAHS Surveys from preoperative to various postoperative timepoints|Change iHOT--33 Surveys from preoperative to various postoperative timepoints|Change LEFS Surveys from preoperative to various postoperative timepoints|Patient Satisfaction Questionnaires|Degree of Improvement on Hip Strength|Degree of Improvement on Hip Range of Motion (ROM)|Degree of Improvement on Hip VAS Pain Score,Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",,40.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,2017P001391/PHS,"June 26, 2017","June 30, 2019","June 30, 2019","April 9, 2019",,"April 9, 2019","MGH, Massachusetts General Hospital, Boston, Massachusetts, United States",76,,No Results Available,https://ClinicalTrials.gov/show/NCT03909139
NCT02958267,Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee,,Completed,Knee Osteoarthritis,Biological: BMAC injection|Biological: PRP injection|Device: Gel-One® hyaluronate injection,Knee Injury and Osteoarthritis Outcome Score|Numeric Pain Rating Scale|Patient Reported Outcome Measurement Information System Global Health Scores,OhioHealth,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 2,32.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,OH1-16-00672,December 2016,August 2018,August 2018,"November 8, 2016","September 24, 2019","September 24, 2019","McConnell Spine, Sport, and Joint Physicians, Columbus, Ohio, United States",77,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02958267/Prot_SAP_000.pdf",Has Results,https://ClinicalTrials.gov/show/NCT02958267
NCT02962661,Trial With Mesenchymal Stromal Cells (MSCs) vs Standard of Care in Cardiomyopathy,,Not yet recruiting,Other Forms of Heart Disease,Biological: Intravenous Infusion of Human Mesenchymal Stem Cells (hMSCs)|Other: Routine Heart Failure Medical Therapy|Biological: Transendocardial Injections of Mesenchymal Stromal Cells,Number of Adverse Events of Allogeneic Human Mesenchymal Stem Cells (hMSCs) Administered by Intravenous Infusion and Transendocardial Injection|Improvement in Left Ventricular Systolic Function (LVEF) Assessed by Left Ventricular Ejection Fraction|Left Ventricular End-Systolic and End-Diastolic Volumes Determined by Contrast-Enhanced 3-D Echography,M.D. Anderson Cancer Center|Texas Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,72.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0835|NCI-2016-01921,"July 30, 2019","July 30, 2023","July 30, 2023","November 11, 2016",,"May 9, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",78,,No Results Available,https://ClinicalTrials.gov/show/NCT02962661
NCT02107118,Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men,,Withdrawn,Erectile Dysfunction|Cardiac Disease,Biological: ARM 1: AdMSC: adipose stem cells|Other: ARM 2: Placebo,Improvements in IIEF scores of greater than 2|Improvements in RHI (reactive hyperemic index) scores of greater than 0.3,Baylor College of Medicine,Male,"40 Years and older   (Adult, Older Adult)",Phase 1,0.0,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,H-34570 No.11-13-40-07,May 2015,March 2020,February 2022,"April 8, 2014",,"May 25, 2015","Baylor College of Medicine, Houston, Texas, United States",79,,No Results Available,https://ClinicalTrials.gov/show/NCT02107118
NCT03799718,Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS,,Recruiting,"Multiple Sclerosis, Chronic Progressive",Biological: NurOwn (MSC-NTF cells),Incidence of treatment-emergent adverse events|Timed 25-foot walking speed or 9-Hole Peg Test - change from baseline.|Number of participants with changes in neurotrophic factors (such as Vascular endothelial growth factor and Hepatocyte growth factor) in the cerebrospinal fluid (CSF) following NurOwn® transplantation,Brainstorm-Cell Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BCT-101-US,"March 13, 2019",February 2020,September 2020,"January 10, 2019",,"July 23, 2019","Stanford University School of Medicine, Redwood City, California, United States|Cleveland Clinic, Cleveland, Ohio, United States",80,,No Results Available,https://ClinicalTrials.gov/show/NCT03799718
NCT01409954,Collecting Bone Graft During Spinal Decompression and Posterolateral Lumbar Fusion to Better Define Bone Making Cells,,Enrolling by invitation,Pseudarthrosis After Fusion or Arthrodesis,,Osteogenic Potential of Mesenchymal Stem Cells,University of Utah,All,"18 Years and older   (Adult, Older Adult)",,60.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,46970,October 2011,January 2021,January 2021,"August 4, 2011",,"July 24, 2019","University of Utah Orthopaedic Center, Salt Lake City, Utah, United States",81,,No Results Available,https://ClinicalTrials.gov/show/NCT01409954
NCT03186417,Mesenchymal Stem Cells in Early Rheumatoid Arthritis,,Recruiting,Rheumatoid Arthritis,Biological: 2 million hMSC/kg|Biological: 4 million hMSC/kg|Biological: 6 million hMSC/kg|Biological: placebo,Safety assessed by dose limiting toxicity (DLT)|Safety assessed by dose limiting toxicity|Safety assessed by change in spirometry|Safety assessed by all adverse events|Change in patient reported outcomes|DAS28-CRP,MetroHealth Medical Center|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,20.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB16-00587|R21AR069226,"December 15, 2017","December 31, 2020","December 31, 2020","June 14, 2017",,"July 10, 2019","UH Hospitals Cleveland, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States",82,,No Results Available,https://ClinicalTrials.gov/show/NCT03186417
NCT03925649,Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI,,No longer available,Spinal Cord Injury at C5-C7 Level,Drug: HB-adMSCs,,"Hope Biosciences|The University of Texas Health Science Center, Houston",Male,"18 Years and older   (Adult, Older Adult)",,,Industry|Other,Expanded Access:Individual Patients|Intermediate-size Population|Treatment IND/Protocol,,Spinal Cord Injury(SCI),,,,"April 24, 2019",,"September 25, 2019","Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston, Texas, United States",83,,No Results Available,https://ClinicalTrials.gov/show/NCT03925649
NCT03325322,Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease,,Recruiting,Chronic Kidney Diseases|Diabetes Mellitus|Diabetic Nephropathies,Dietary Supplement: Fisetin|Drug: Placebo oral capsule,Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization|Mesenchymal stem cells in vitro including cell migration|Mesenchymal stem cells -molecular characteristics examined by second generation sequencing,Mayo Clinic,All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,30.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",16-010521,"January 2, 2018",January 2021,April 2022,"October 30, 2017",,"September 17, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States",84,,No Results Available,https://ClinicalTrials.gov/show/NCT03325322
NCT03672825,REcycled CartiLage Auto/Allo IMplantation,,Recruiting,Cartilage Defect,Drug: REcycled CartiLage Auto/Allo IMplantation,"Nature, incidence and severity of adverse events (AEs)",Mayo Clinic,All,18 Years to 50 Years   (Adult),Phase 1,25.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-000939,"September 13, 2018","September 13, 2022","September 13, 2022","September 17, 2018",,"October 11, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",85,,No Results Available,https://ClinicalTrials.gov/show/NCT03672825
NCT01033552,"Biochemical Correction of Severe EB by Allo HSCT and ""Off-the-shelf"" MSCs",,Recruiting,Epidermolysis Bullosa,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Anti-thymocyte globulin|Drug: Cyclosporine A|Drug: Mycophenolate mofetil|Procedure: Mesenchymal stem cell transplantation|Radiation: Total body irradiation|Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation,Event-free survival rate|Transplant-related mortality (TRM)|Pattern of biochemical improvement|Quality of Life|Durability of HSC and third party MSC engraftment in the skin|Probability of Survival|Acute GVHD,"Masonic Cancer Center, University of Minnesota",All,"up to 25 Years   (Child, Adult)",Phase 2,75.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MT2009-09|0911M74035,January 2010,October 2019,October 2019,"December 16, 2009",,"September 25, 2019","University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",86,,No Results Available,https://ClinicalTrials.gov/show/NCT01033552
NCT01775774,Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome,START,Completed,Acute Respiratory Distress Syndrome,Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells,Incidence of Pre-specified Infusion Associated Adverse Events|Incidence of Severe Adverse Events (SAEs)|Ventilator Free Days at Study Day 28|Duration of Vasopressor Use (Days)|ICU Free Days to Day 28|Hospital Survival to Day 60|Mortality at Hospital Discharge,"Michael A. Matthay|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital|Stanford University|University of Pittsburgh|University of Minnesota - Clinical and Translational Science Institute|University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ARDS MSC 001|1U01HL108713-01,July 2013,February 2014,February 2015,"January 25, 2013","August 14, 2017","August 14, 2017","University of California San Francisco Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",87,,Has Results,https://ClinicalTrials.gov/show/NCT01775774
NCT01733186,"Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects",,Completed,Degeneration Articular Cartilage Knee,Biological: CARTISTEM®,Number of adverse events|Improvement in IKDC score|Improvement in knee function and pain and grade of cartilage regeneration,Medipost Co Ltd.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,12.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MP-0201-01,"January 7, 2013","June 2, 2017","August 29, 2017","November 26, 2012",,"August 29, 2018","Cartilage Restoration Center; RUSH University Medical Center, Chicago, Illinois, United States|Cartilage Repair Center; Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States",88,,No Results Available,https://ClinicalTrials.gov/show/NCT01733186
NCT01392625,PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study),PoseidonDCM,Completed,Non-ischemic Dilated Cardiomyopathy,Biological: Autologous hMSCs|Biological: Allogeneic hMSCs,Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)|Measurement of Changes in Peak VO2|Measurement of Changes in 6 Minute Walk|Measurement of Changes in Global Ejection Fraction|Measurement of Changes in New York Heart Association (NYHA)|Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire,"Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami",All,"18 Years to 95 Years   (Adult, Older Adult)",Phase 1|Phase 2,37.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20100968|1R01HL110737-01,"May 19, 2011","August 28, 2016","August 28, 2017","July 12, 2011","February 15, 2018","February 15, 2018","University of Miami School of Medicine, Miami, Florida, United States",89,,Has Results,https://ClinicalTrials.gov/show/NCT01392625
NCT00284986,Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients,,Completed,Graft Versus Host Disease,Drug: Prochymal (TM),Primary efficacy endpoint|- Response by Day 28|Secondary efficacy endpoints|Improvement of GVHD by day 28 in one or more organs|involved with GVHD symptoms at day 1|Time to best overall GVHD grade|Best stage of each involved organ by day 28|Time to improvement or resolution of GVHD in one or|more organs|Safety Endpoints|Adverse events|Infusional toxicity|Overall relapse of underlying disease|Overall survival|Formation of ectopic tissue foci|Incidence of infection,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"6 Months to 70 Years   (Child, Adult, Older Adult)",Phase 2,15.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Osiris 270,November 2005,February 2007,February 2007,"February 1, 2006",,"December 4, 2014","Duke University, Durham, North Carolina, United States",90,,No Results Available,https://ClinicalTrials.gov/show/NCT00284986
NCT03754465,Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers,,Recruiting,Diabetic Foot Ulcer,Biological: ALLO-ASC-DFU|Procedure: Hydrogel SHEET(Vehicle control),"Proportions of subjects who achieved complete wound closure|Time to initial complete wound closure between the two groups|Changes in wound size compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, Plantar and the other location between the two groups|Durability of complete wound closure","Anterogen Co., Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,44.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",ALLO-ASC-SHEET-102,November 2018,December 2019,March 2020,"November 27, 2018",,"November 27, 2018","University of Southern California, Los Angeles, California, United States",91,,No Results Available,https://ClinicalTrials.gov/show/NCT03754465
NCT02582775,MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs,,Recruiting,Epidermolysis Bullosa,Drug: Thymoglobulin|Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Bone marrow infusion|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Biological: Donor mesenchymal stem cell infusions|Drug: Busulfan,Event-free survival|Percentage change of a patient's iscorEB|Transplant-related mortality|Quality of life|Lymphoid Chimerism|Myeloid Chimerism,"Masonic Cancer Center, University of Minnesota",All,"up to 25 Years   (Child, Adult)",Phase 2,84.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015LS076,March 2016,September 2021,September 2022,"October 21, 2015",,"March 29, 2019","University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",92,,No Results Available,https://ClinicalTrials.gov/show/NCT02582775
NCT00294112,Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease,,Completed,Crohn's Disease,Drug: Prochymal™ adult human mesenchymal stem cells|Drug: adult human mesenchymal stem cells,Crohn's disease activity index|Inflammatory bowel disease quality-of-life questionnaire|Crohn's disease endoscopic index of severity|Crohn's remission,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,10.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSIRIS-601-602,February 2006,August 2006,September 2008,"February 20, 2006",,"December 4, 2014","Osiris Clinical Site, Baton Rouge, Louisiana, United States|Osiris Clinical Site, Charlotte, North Carolina, United States|Osiris Clinical Site, Pittsburgh, Pennsylvania, United States|Osiris Clinical Site, Richmond, Virginia, United States",93,,No Results Available,https://ClinicalTrials.gov/show/NCT00294112
NCT02600130,Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease,,Recruiting,Alzheimer's Disease,Biological: Longeveron Mesenchymal Stem Cells|Biological: Placebo,To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.|Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.,Longeveron LLC,All,"50 Years to 80 Years   (Adult, Older Adult)",Phase 1,30.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",00-0000-01,August 2016,March 2020,March 2020,"November 9, 2015",,"December 17, 2018","UCLA School of Medicine, Los Angeles, California, United States|Brain Matters Research, Delray Beach, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Miami Jewish Health, Miami, Florida, United States",94,,No Results Available,https://ClinicalTrials.gov/show/NCT02600130
NCT03478215,Mesenchymal Stromal Cells in Living Donor Kidney Transplantation,,Recruiting,Renal Transplantation|Mesenchymal Stem Cells,Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion|Other: Normal Saline (Placebo) Infusion,"Number of participants without any infusional toxicity, occurring within 24 hours of infusion.|Number of participants without any acute rejection, graft loss, or death at 6 months post transplant.","The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,24.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other",Pro00012858|U1111-1169-2289,February 2016,July 2021,July 2021,"March 27, 2018",,"September 2, 2019","Houston Methodist Hospital System, Houston, Texas, United States",95,,No Results Available,https://ClinicalTrials.gov/show/NCT03478215
NCT02384018,Mesenchymal Stem Cell and Islet Co-transplantation,,Completed,Chronic Pancreatitis|Diabetes,Biological: autologous mesenchymal stromal cell,"C-peptide level after mixed meal tolerance test|Liver function, kidney function|The absence of severe hypoglycemic episodes",Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 69 Years   (Adult, Older Adult)",Phase 1,24.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCT-BMMSC15-001|5R21DK099696,December 2014,December 2018,December 2018,"March 10, 2015",,"January 3, 2019","GI Surgery, Medical University of South Carolina, Charleston, South Carolina, United States",96,,No Results Available,https://ClinicalTrials.gov/show/NCT02384018
NCT03857841,A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD,,Recruiting,Bronchopulmonary Dysplasia,Biological: UNEX-42|Biological: Phosphate-buffered saline,"Number of Subjects With Treatment-emergent Adverse Events During the Post-treatment Phase (Safety and Tolerability)|Incidence of BPD at 36 Weeks Post-menstrual Age|Incidence of Death at 36 Weeks Post-menstrual Age|Severity of BPD (mild, moderate, severe) at Week 36 Post-menstrual Age",United Therapeutics,All,up to 14 Days   (Child),Phase 1,18.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UNX-BP-101,"June 20, 2019",December 2021,December 2021,"February 28, 2019",,"September 18, 2019","University of Colorado Hospital, Aurora, Colorado, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States",97,,No Results Available,https://ClinicalTrials.gov/show/NCT03857841
NCT00826046,Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD,,No longer available,Graft-Versus-Host Disease,Drug: Prochymal®,,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",,,Industry,Expanded Access,,276,,,,"January 21, 2009",,"October 22, 2015","Indiana BMT, Beech Grove, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",98,,No Results Available,https://ClinicalTrials.gov/show/NCT00826046
NCT00187018,Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study,,Completed,Osteogenesis Imperfecta,Biological: Bone marrow transplant,To find out the effects (good and bad) of bone marrow cell infusions using donor bone marrow that has had CD3+ cells removed|To find out if there is any effect on the growth rate of children with osteogenesis imperfecta who receive donor bone marrow which has had CD3+ cells removed|To find out if there is any effect on the total bone mineral content of children with OI|who receive donor bone marrow which has had CD3+ cells removed|To find out the effect of the CD3 washed-out marrow cell therapy on the growth rate of the children,St. Jude Children's Research Hospital,All,"Child, Adult, Older Adult",Not Applicable,9.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STOD2,March 2004,August 2007,August 2007,"September 16, 2005",,"March 4, 2015","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",99,,No Results Available,https://ClinicalTrials.gov/show/NCT00187018
NCT03489564,Mitochondrial Capacity in Pregnant Women,Mito Moms,Recruiting,Pregnancy Related|Physical Activity,Behavioral: Active|Behavioral: Sedentary,Infant in vitro mitochondrial capacity (by oxygen consumption rate)|Relationship between in vivo mitochondrial capacity and infant in vitro mitochondrial capacity (by oxygen consumption rates)|Relationship between in vivo mitochondrial capacity and maternal in vitro mitochondrial capacity (by oxygen consumption rate),Pennington Biomedical Research Center,Female,18 Years to 40 Years   (Adult),,20.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,PBRC 2017-065,"March 19, 2018","December 31, 2019","December 31, 2019","April 5, 2018",,"May 23, 2019","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",100,,No Results Available,https://ClinicalTrials.gov/show/NCT03489564
NCT02674399,A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis,,"Active, not recruiting","Osteoarthritis, Knee",Drug: JointStem|Drug: Synvisc-One,Change from baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) score in JointStem group|Change from baseline on Visual Analog Scale (VAS) in JointStem group|MRI Improvement Evaluation in JointStem group|Change from baseline on WOMAC between JointStem and positive control groups|Change from baseline on VAS between JointStem and positive control groups|Change from baseline on Knee Injury & Osteoarthritis Outcome Score (KOOS) between JointStem and positive control groups|Change from baseline on Lysholm Knee Scoring Scale between JointStem and positive control groups|Change from baseline on International Knee Documentation Committee (IKDC) between JointStem and positive control groups|Change from baseline on RAND-36 Score between JointStem and positive control groups|Change from baseline on WOMAC in JointStem group|Change from baseline on VAS in JointStem group|Comparison of MRI improvement evaluation in JointStem group|Incidence of adverse events and laboratory abnormalities,"Nature Cell Co. Ltd.|KCRN Research, LLC",All,22 Years to 60 Years   (Adult),Phase 2,28.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",JS-OAP2-US01,"February 16, 2016","March 12, 2018",May 2019,"February 4, 2016",,"May 9, 2019","Orthopedic Pain Specialists, Santa Monica, California, United States|Walnut Creek, California, United States",101,,No Results Available,https://ClinicalTrials.gov/show/NCT02674399
NCT00768066,The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT),TAC-HFT,Completed,"Stem Cell Transplantation|Ventricular Dysfunction, Left",Biological: Autologous human mesenchymal cells (hMSCs)|Biological: Autologous human bone marrow cells (hBMCs)|Biological: Placebo,"Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|Serial Troponin Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Serial Creatine Kinase Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Incidence of the Major Adverse Cardiac Events (MACE) Endpoint, Defined as the Composite Incidence of (1) Death, (2) Hospitalization for Heart Failure, or (3) Non-fatal Recurrent MI.|Ectopic Tissue Formation.|Number of Deaths|Change From Baseline in Distance Walked in Six-minutes (Six-minute Walk Test).|Change From Baseline in the Minnesota Living With Heart Failure (MLHF) Questionnaire Total Score.|Percent Change From Baseline in Scar Mass as a Fraction of Left Ventricle Mass by Cardiac MRI or CT.","University of Miami|The Emmes Company, LLC",All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,65.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",20070443,August 2008,August 2012,September 2013,"October 7, 2008","December 14, 2015","December 14, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States",102,,Has Results,https://ClinicalTrials.gov/show/NCT00768066
NCT02846883,Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms,VIVAAA,Recruiting,Abdominal Aortic Aneurysm,Biological: MSC's|Drug: Placebo,Incidence of treatment related adverse events at 12 months post MSC administration as evidenced by the Investigator|Changes in circulating inflammatory cell phenotypes as measured by 18-FDG PET/CT,VA Office of Research and Development,All,"40 Years to 85 Years   (Adult, Older Adult)",Phase 1,36.0,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CLNB-06-15F|1510579216,"December 5, 2016","June 1, 2020","June 1, 2021","July 27, 2016",,"July 23, 2019","Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States",103,,No Results Available,https://ClinicalTrials.gov/show/NCT02846883
NCT02104713,Stem Cell Therapy to Improve Burn Wound Healing,,"Active, not recruiting",Skin Burn Degree Second,Biological: Allogeneic (MSC's) Application to the Burn Wounds,Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.,E.Badiavas|United States Department of Defense|University of Miami,All,"18 Years and older   (Adult, Older Adult)",Phase 1,20.0,Other|U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,20120925,April 2014,February 2020,February 2020,"April 4, 2014",,"October 1, 2019","University of Miami, Miami, Florida, United States",104,,No Results Available,https://ClinicalTrials.gov/show/NCT02104713
NCT02396056,Enhancing Guided Bone Regeneration by Modifying a Resorbable Membrane,,Unknown status,Alveolar Ridge Augmentation,Other: BioMend Extend|Other: Modified BioMend Extend,Clinical horizontal bone augmentation results through direct measurement.|Volumetric measurements with CBCT,Stony Brook University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,10.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,StonyBrookU,December 2014,December 2017,December 2017,"March 24, 2015",,"October 17, 2016","School of Dental Medicine of Stony Brook University, Stony Brook, New York, United States",105,,No Results Available,https://ClinicalTrials.gov/show/NCT02396056
NCT02468492,Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation,,Completed,Knee Osteoarthritis,Biological: Platelet Rich Plasma|Other: Normal Saline,Biochemical Molecular Outcomes|Clinical Outcomes|Imaging Outcomes,Hunter Holmes Mcguire Veteran Affairs Medical Center|Foundation for Physical Medicine and Rehabilitation,All,"40 Years and older   (Adult, Older Adult)",Early Phase 1,18.0,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,IRB #01979/FDA IDE#15944,September 2014,November 2015,November 2015,"June 10, 2015",,"August 16, 2017","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States",106,,No Results Available,https://ClinicalTrials.gov/show/NCT02468492
NCT00186914,Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation,,Completed,Osteodysplasia,Biological: Marrow stromal cell infusion,To evaluate the safety of the stromal cell infusion,St. Jude Children's Research Hospital|Drexel University|Wayne State University,All,"Child, Adult, Older Adult",Phase 1,8.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STOD,July 1999,November 2001,January 2008,"September 16, 2005",,"March 4, 2015","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",107,,No Results Available,https://ClinicalTrials.gov/show/NCT00186914
NCT01558908,Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia,,Unknown status,Peripheral Vascular Diseases,Biological: Administration of ERC,Safety|Efficacy,Medistem Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,15.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEDS-027,May 2012,May 2013,July 2013,"March 20, 2012",,"March 20, 2012","Indiana University School of Medicine, Indianapolis, Indiana, United States",108,,No Results Available,https://ClinicalTrials.gov/show/NCT01558908
NCT03117738,A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease,,"Active, not recruiting",Alzheimer Disease,Drug: AstroStem|Other: Placebo-Control,"Treatment related adverse events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|MMSE (Mini-mental status examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale)|MRI Scan|Biomarkers: Amyloid beta 40, Amyloid beta 42, Amyloid precursor protein intracellular domain (AICD), soluble neuregulin-1 (sNRG-1)",Nature Cell Co. Ltd.,All,"50 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AST-ADP2-US01,"April 3, 2017",August 2019,September 2019,"April 18, 2017",,"May 9, 2019","ATP Clinical Research, Costa Mesa, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Valden Medical, Honolulu, Hawaii, United States",109,,No Results Available,https://ClinicalTrials.gov/show/NCT03117738
NCT03838250,Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC,,Recruiting,Alcoholic Liver Cirrhosis,Biological: Cellgram™ (Bone marrow-derived MSCs),Incidence of Serious Adverse Events|Number of patients with Hepatocellular carcinoma (primary liver cancer) development|Incidence of Adverse Events|Liver stiffness measurement|How well the Liver is functioning|Chronic liver disease as assessed by the Child-Pugh score|Model for End-Stage Liver Disease (MELD) Score|Overall survival|Quality of life as assessed by 36-Item Short Form Survey (SF-36) Questionnaire,"Pharmicell Co., Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,10.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PMC-P-08,"June 20, 2019",March 2021,June 2021,"February 12, 2019",,"July 4, 2019","University of Utah, Salt Lake City, Utah, United States",110,,No Results Available,https://ClinicalTrials.gov/show/NCT03838250
NCT03896568,Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma,,Recruiting,IDH1 wt Allele|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma,Biological: Oncolytic Adenovirus Ad5-DNX-2401|Procedure: Therapeutic Conventional Surgery,Maximum-tolerated dose (MTD)|Incidence of adverse events (AEs)|Tumor response|Time to progression|Virus replication in tumor|Virus shedding|Immunogenicity based on adenoviral (AdV) antibodies,M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,36.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-0953|NCI-2019-01195|P30CA016672,"February 12, 2019","February 28, 2020","February 28, 2020","April 1, 2019",,"April 1, 2019","M D Anderson Cancer Center, Houston, Texas, United States",111,,No Results Available,https://ClinicalTrials.gov/show/NCT03896568
NCT00790764,Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI),,Suspended,Heart Disease|Blocked Arteries|Coronary Ischemia|Coronary Disease|Coronary Artery Disease|Coronary Atherosclerosis,Biological: MESENDO|Other: placebo,"Safety as measured by laboratory assessments, ecg and temperature.|Efficacy as measured by SPECT scan, MUGA scan and 2D Echogradiogram",TCA Cellular Therapy,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,60.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2008--03-II,November 2008,May 2014,May 2014,"November 13, 2008",,"May 9, 2014","TCA Cellular Therapy, Covington, Louisiana, United States",112,,No Results Available,https://ClinicalTrials.gov/show/NCT00790764
NCT01166776,A Research Study Looking at Specific Tissue of the Umbilical Cord,,Completed,Varices of Umbilical Cord,,Isolation and decellularization of umbilical cord Wharton's jelly matrix|Study the ability of the isolated and decellularized matrix to support recellularization with mesenchymal stem cells and to support their growth and differentiation,University of Kansas Medical Center|Children's Mercy Hospital Kansas City,Female,"18 Years and older   (Adult, Older Adult)",,64.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,12129,June 2010,April 2016,July 2016,"July 21, 2010",,"August 22, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States|Children's Mercy Hospital, Kansas City, Missouri, United States",113,,No Results Available,https://ClinicalTrials.gov/show/NCT01166776
NCT03268603,Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS),,Recruiting,ALS|Amyotrophic Lateral Sclerosis,Drug: Autologous Adipose-derived Mesenchymal Stromal Cells,Number of Adverse Events|Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R),Mayo Clinic|State of Minnesota Regenerative Medicine Minnesota,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-008008|UL1TR000135,"October 10, 2017",December 2019,December 2019,"August 31, 2017",,"April 11, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",114,,No Results Available,https://ClinicalTrials.gov/show/NCT03268603
NCT01770613,A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI),,Withdrawn,ST Segment Elevation Myocardial Infarction (STEMI)|Allogeneic Mesenchymal Bone Marrow Cells,Biological: Stem cells,"The safety and tolerability of aMBMC intravenous administration during the twelve month study period as determined by major adverse events MACE endpoint.|The change from baseline on physical exam conducted at day 14 and at 1, 3, 6 and 12 months post-administration, as available:|• LV end diastolic volume|• LV end systolic volume|• Infarct size measured by MRI, with and without contrast (only for patients eligible for MRI)|• Global Left Ventricular Ejection Fraction (measured by echocardiography)|• SF-36 Health Assessment|• Incidence of Ventricular Arrhythmias requiring intervention at 1 and 3 months post-administration","Stemedica Cell Technologies, Inc.|CardioCell LLC",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,0.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",STEM 103-M-STEMI,February 2013,May 2016,May 2017,"January 18, 2013",,"April 27, 2017","Mercy Gilbert and Chandler Medical Center, Gilbert, Arizona, United States|Emory University Hospital, Atlanta, Georgia, United States",115,,No Results Available,https://ClinicalTrials.gov/show/NCT01770613
NCT02017912,"Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS",NurOwn,Completed,Amyotrophic Lateral Sclerosis (ALS),Biological: Autologous MSC-NTF cells|Biological: Placebo,Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation,Brainstorm-Cell Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,48.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BCT-001-US,May 2014,March 2016,July 2016,"December 23, 2013",,"July 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",116,,No Results Available,https://ClinicalTrials.gov/show/NCT02017912
NCT01931007,Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis,BMAC,Completed,Bilateral Primary Osteoarthritis of Knee,Drug: Autologous Bone Marrow Aspirate Concentrate|Drug: Sterile saline,Number of Subjects with Adverse Reactions to Concentrated Mesenchymal Stem Cells (MSCs)|Mean Knee Cartilage,Mayo Clinic,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 1,25.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,12-004459,August 2013,January 2016,January 2016,"August 29, 2013",,"May 5, 2017","Mayo Clinic Jacksonville, Jacksonville, Florida, United States",117,,No Results Available,https://ClinicalTrials.gov/show/NCT01931007
NCT01366911,Stem Cells Predicting Orthopedic Outcomes,,Completed,Hip Arthroplasty,,Can Stem Cells Predict Orthopaedic Outcomes?,University of Nebraska,All,"Child, Adult, Older Adult",,203.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,168-11-FB,April 2011,"January 10, 2014","January 10, 2014","June 6, 2011",,"September 14, 2017","Dept of Orthopaedic Surgery at University of Nebraska Medical Center, Omaha, Nebraska, United States|Dept. of Orthopaedic Surgery, Omaha, Nebraska, United States",118,,No Results Available,https://ClinicalTrials.gov/show/NCT01366911
NCT03818737,Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES),MILES,Recruiting,Osteoarthritis,Biological: Autologous Bone Marrow Concentrate (BMAC)|Biological: Adipose-derived Stromal Vascular Fraction (SVF)|Biological: Umbilical Cord Tissue (UCT)|Drug: Depomedrol and Normal saline (Corticosteroid injection),Change in Visual Analog Pain Scale (VAS-pain) scores|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS)|Change in EuroQuality of Life (EQ5D-3L) scores|Change in Patient-Reported Outcomes Measurement Information System (PROMIS 29) scores,Emory University|The Marcus Foundation,All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 3,480.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,IRB00108046,"March 28, 2019","December 31, 2021","December 31, 2021","January 28, 2019",,"June 10, 2019","Andrews Institute, Gulf Breeze, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Duke University, Durham, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Sanford Health, Sioux Falls, South Dakota, United States",119,,No Results Available,https://ClinicalTrials.gov/show/NCT03818737
NCT03525418,Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS),ELPIS,Recruiting,HLHS,Biological: Longeveron Mesenchymal Stem Cells,"Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events.|Efficacy: Change from baseline in right ventricular ejection fraction (%).|Efficacy: Change from baseline in right ventricular end-systolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic diameter.|Efficacy: Change from baseline tricuspid regurgitation.|Efficacy: Change in weight (in kilograms).|Efficacy: Change in height (in centimeters).|Efficacy: Change in head circumference (in centimeters).|Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial.",Longeveron LLC,All,up to 1 Year   (Child),Phase 1|Phase 2,30.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",00-0000-05,"February 21, 2018",February 2021,February 2022,"May 15, 2018",,"October 8, 2018","Emory University/Childen's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University Hospital, Baltimore, Maryland, United States|C.S Mott Children's Hospital/University of Michigan Congenital Heart Center, Ann Arbor, Michigan, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Utah/Heart Center-Primary Children's Hospital, Salt Lake City, Utah, United States",120,,No Results Available,https://ClinicalTrials.gov/show/NCT03525418
NCT03379168,Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.,,Recruiting,Knee Osteoarthritis,Device: Microfragmented Adipose Tissue (Lipogems)|Drug: Corticosteroid injection|Drug: Saline,Change in Visual Analog Pain Scale (VAS) Over Time|Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Over Time|Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Over Time,"Dustin L. Richter, MD|University of New Mexico",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,17-146,"April 1, 2018","March 31, 2019",July 2019,"December 20, 2017",,"April 23, 2018","UNM Hospital, Albuquerque, New Mexico, United States",121,,No Results Available,https://ClinicalTrials.gov/show/NCT03379168
NCT04007081,Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia,,Recruiting,Xerostomia|Head and Neck Cancer,Procedure: Bone Marrow Aspiration|Diagnostic Test: Ultrasound Imaging of Salivary Glands|Other: Salivary Assay|Other: Quality of Life Instruments,Number of Participant's whose Marrow-Derived MSCs Can be Expanded in vitro to > 50 million cells within two weeks|Change in participant QoL: XeQOL|Change in participant QoL: MDADI|Change in participant QoL: VAS|Change in participant Salivary Function: Unstimulated|Change in participant Salivary Function: Stimulated|Change in participant Salivary Gland Size,"University of Wisconsin, Madison",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,15.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,UW19009|2019-0497|SMPH/HUMAN ONCOLOGY/HUMAN ONCO,October 2019,"January 31, 2021","January 31, 2021","July 3, 2019",,"September 6, 2019","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States",122,,No Results Available,https://ClinicalTrials.gov/show/NCT04007081
NCT02982915,Human Mesenchymal Stem Cells (LMSCs) on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty,HERA,Recruiting,Aging Frailty,Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Biological: Fluzone High Dose Vaccine,"The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:|Changes from baseline through month 12 in adaptive immunity and primary B cell response to the influenza vaccine in subjects with Aging Frailty.|Post-vaccination changes from baseline in the influenza specific plasmablast differential between the LMSC and Placebo Cohorts|Changes from baseline between the LMSC and Placebo Cohorts as assessed by biomarkers|Differences in rate of decline from Aging Frailty|Changes in subject quality of life (QOL)|Death from any cause",Longeveron LLC,All,65 Years to 90 Years   (Older Adult),Phase 1|Phase 2,83.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",00-0000-03,November 2016,June 2019,December 2019,"December 6, 2016",,"December 10, 2018","Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|University of Miami, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Optimal Research LLC, Rockville, Maryland, United States",123,,No Results Available,https://ClinicalTrials.gov/show/NCT02982915
NCT02181478,Intra-Osseous Co-Transplant of UCB and hMSC,,Recruiting,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Myelofibrosis|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Lymphoid Malignancies|Chronic Myelogenous Leukemia,Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Procedure: mesenchymal stem cell transplantation,Number of patients with BM cellularity failure: Measure of feasibility|Number of patients with ANC failure without evidence of disease: Measure of feasibility|Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility|Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Rate of neutrophil recovery|Rate of platelet recovery|Median time of neutrophil recovery|Median time of platelet recovery,Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years to 75 Years   (Adult, Older Adult)",Early Phase 1,12.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CASE1Z14|NCI-2014-01316|P30CA043703,"July 22, 2015",May 2020,May 2020,"July 4, 2014",,"May 27, 2019","Case Comprehensive Cancer Center, Cleveland, Ohio, United States",124,,No Results Available,https://ClinicalTrials.gov/show/NCT02181478
NCT02503280,The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.,TAC-HFT-II,Not yet recruiting,Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction,Drug: Autologous hMSCs|Drug: Autologous Human C-Kit CSCs II|Drug: Placebo|Device: Biosense Webster MyoStar NOGA Injection Catheter System,Incidence of any treatment emergent serious adverse events (TE-SAEs)|Treatment Emergent adverse event rates|Ectopic tissue formation|48-hour ambulatory electrocardiogram (ECG) recordings.|Hematology value changes post-catheterization|Urinalysis results changes post-catheterization|Clinical chemistry values post-catheterization|Pulmonary function|Serial troponin I values|Creatine kinase-MB (CK-MB) value changes post-catheterization|Post-cardiac catheterization echocardiogram.|Magnetic resonance imaging (MRI) measures of infarct scar size (ISS)|Echocardiographic measures of infarct scar size (ISS)|Magnetic resonance imaging (MRI) of Left Regional Ventricular Function|Echocardiographic measures of Left Regional Ventricular Function|Magnetic resonance imaging (MRI) of Global Ventricular Function|Echocardiographic measures of Global Ventricular Function|Tissue perfusion measured by MRI.|Peak oxygen consumption (Peak VO2) (by treadmill determination).|Six-minute walk test.|New York Heart Association (NYHA) functional class.|Minnesota Living with Heart Failure (MLHF) questionnaire.|Incidence of Major Adverse Cardiac Events (MACE),Joshua M Hare|University of Miami,All,"21 Years to 89 Years   (Adult, Older Adult)",Phase 1|Phase 2,55.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,20120203,"March 1, 2025",March 2030,March 2032,"July 20, 2015",,"October 3, 2019","ISCI / University of Miami, Miami, Florida, United States",125,,No Results Available,https://ClinicalTrials.gov/show/NCT02503280
NCT01771679,Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging,,Suspended,Chronic Effect of Ultraviolet Radiation on Photoaged Skin|Dermatologic Disorders,Biological: Allogeneic Mesenchymal Bone Marrow Cells,MSC Safety and Tolerability|MSC Efficacy,"Stemedica Cell Technologies, Inc.|StemCutis, LLC - A Stemedica Company",All,"40 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,29.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STEM 102-M,July 2015,November 2018,May 2019,"January 18, 2013",,"April 17, 2018","eStudy Site, La Mesa, California, United States|Naval Medical Center San Diego, San Diego, California, United States",126,,No Results Available,https://ClinicalTrials.gov/show/NCT01771679
NCT03294759,Bio ACL Reconstruction Amnion Collagen Matrix Wrap and Stem Cells,Bio ACL RCT,"Active, not recruiting",ACL - Anterior Cruciate Ligament Rupture,Other: Bio ACL|Other: Control,Changes in ACL|Changes in patient-reported pain rating|Changes in Knee injury and Osteoarthritis Outcome Score (KOOS)|Changes in Short Form 12 (SF-12) patient ratings|Changes in Single Assessment Numerical Evaluation (SANE) patient ratings for function|Marx Activity Scale Rating,"Andrews Research & Education Foundation|Arthrex, Inc.",All,18 Years to 45 Years   (Adult),Not Applicable,40.0,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",Bio ACL (RCT),"September 6, 2017","September 19, 2020","February 25, 2021","September 27, 2017",,"October 1, 2019","Andrews Institute, Gulf Breeze, Florida, United States",127,,No Results Available,https://ClinicalTrials.gov/show/NCT03294759
NCT02582489,Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy,,Not yet recruiting,Osteoarthritis Post-meniscectomy,Biological: Bone Marrow Aspirate Concentrate|Procedure: Standard Meniscectomy,International Knee Documentation Committee (IKDC) Score|Patient reported outcomes throughout follow-up period|Synovial fluid analysis|Radiographic analysis,Rush University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",15090903,April 2017,January 2019,January 2020,"October 21, 2015",,"April 14, 2017","Rush University Medical Center, Chicago, Illinois, United States",128,,No Results Available,https://ClinicalTrials.gov/show/NCT02582489
NCT00702741,Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy,,Completed,Recovery Following Partial Medial Meniscectomy,Drug: Chondrogen|Drug: Placebo,Comparison of treatment adverse event rates|Concomitant Medications|Visual Analog Scale,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,55.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",551,June 2008,September 2011,September 2011,"June 20, 2008",,"December 4, 2014","University of Southern California Keck School of Medicine, Los Angeles, California, United States|OrthoIndy, Indianapolis, Indiana, United States|TRIA Orthopaedic Center, Bloomington, Minnesota, United States|Unlimited Research, San Antonio, Texas, United States",129,,No Results Available,https://ClinicalTrials.gov/show/NCT00702741
NCT02633163,Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE),,Recruiting,Systemic Lupus Erythematosus,Drug: Low Dose Mesenchymal Stem Cells (MSCs)|Drug: High Dose Mesenchymal Stem Cells (MSCs)|Drug: Placebo Infusion,Clinical response at Week 24 as defined by the SLE Responder Index (SRI):|Change in SLEDAI score between groups|Renal and non-renal organ system flares|Changes in SLICC-DI|Changes in HR-QOL|Changes in Fatigue|Changes in Pain|Changes in Depression|Changes in patient-reported lupus-specific disease status|Steroid-sparing effect|Cumulative systemic steroid dose|Changes in the presence of serum and urine biomarkers of SLE activity:,Medical University of South Carolina,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,81.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MUSC-UCMSC-001,"October 26, 2018",June 2021,June 2021,"December 17, 2015",,"April 1, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California - San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States",130,,No Results Available,https://ClinicalTrials.gov/show/NCT02633163
NCT03840343,Patient-derived Stem Cell Therapy for Diabetic Kidney Disease,,Not yet recruiting,"Diabetic Kidney Disease|Diabetic Nephropathies|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Chronic Kidney Disease|Diabetic Nephropathy Type 2|Kidney Failure|Kidney Insufficiency",Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose,Adverse Events|Kidney Function,Mayo Clinic|Regenerative Medicine Minnesota,All,"55 Years to 75 Years   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-002423|RMM 091718 CT 001,May 2019,December 2024,December 2025,"February 15, 2019",,"May 14, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",131,,No Results Available,https://ClinicalTrials.gov/show/NCT03840343
NCT04126603,Impact of Semaglutide on CD34+ EPC and Fat Derived MSC,,Recruiting,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebos,CD34+ Endothelial Progenitor Cell number|CD34+ Endothelial Progenitor Cell Migration against serum SDF1a gradient|Gene Expression of CD34+ Endothelial Progenitor Cell number|Gene Expression of Subcutaneous Adipose cell|Arterial Stiffness: Pulse Wave Velocity|Arterial Stiffness: Pulse Wave Analysis|Body Composition: BMI|Body Composition: Body Fat Percent|Hip to Waist Ratio|Biochemistry: HbA1c|Biochemistry: LDL over HDl Ratio,Sabyasachi Sen|George Washington University,All,"30 Years to 70 Years   (Adult, Older Adult)",Phase 3,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NCR191206,"August 1, 2019","August 1, 2021","November 30, 2021","October 15, 2019",,"October 15, 2019","The GW Medical Faculty Associates, Washington, District of Columbia, United States",132,,No Results Available,https://ClinicalTrials.gov/show/NCT04126603
NCT00366145,Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease,,Completed,Graft Versus Host Disease,Biological: Mesenchymal Stem Cells|Biological: placebo,Complete Response of greater than or equal to 28 days duration|Survival at 180 days post first infusion,Osiris Therapeutics,All,"6 Months to 70 Years   (Child, Adult, Older Adult)",Phase 3,240.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",280,July 2006,May 2009,May 2009,"August 21, 2006",,"October 13, 2011","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Cancer Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Univeristy of California San Francisco, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|All Children's Hospital, St. Petersburg, Florida, United States|Emory University, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northwestern Center for Clinical Research, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois - Chicago, Chicago, Illinois, United States|Indiana Blood and Bone Marrow Transplant Center, Beech Grove, Indiana, United States|Univeristy of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Louisiana State University, Shreveport, Louisiana, United States|University of Maryland/Greenbaum, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos/Wayne State University, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Univeristy of Mississippi Medical Center, Jackson, Mississippi, United States|University of Nebraska, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park, Buffalo, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University/New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest Univeristy School of Medicine, Winston Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Baylor University, Dallas, Texas, United States|Univeristy of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Research Center, San Antonio, Texas, United States|Virginia Commonwealth/Massey Cancer Center, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Wisconsin Madison, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Royal Brisbane Hospital, Herston, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Co-Medica Research Network, Calgary, Alberta, Canada|British Columbia's Children's Hospital, Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|London Health Sciences Centre- Westminster Campus, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Hopital Enfant-Jesus, Quebec, Canada|Hopital du Saint-Sacrement, Quebec, Canada|Universia degli Studi di Pesaro, Pesaro, PU, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Kantonsspital Basel, Basel, Switzerland|Barts & London School of Medicine, London, England, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom|Bristol Royal Hospital for Children, Bristol, UK, United Kingdom|Glasgow Royal Infirmary, Glasgow, UK, United Kingdom|Leeds General Infirmary, Leeds, UK, United Kingdom",133,,No Results Available,https://ClinicalTrials.gov/show/NCT00366145
NCT00683722,PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),,Completed,"Pulmonary Disease, Chronic Obstructive|Pulmonary Emphysema|Chronic Bronchitis",Drug: PROCHYMAL™|Drug: Placebo,Safety|Pulmonary Function Tests|Exercise Capability|Quality of life,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"40 Years to 80 Years   (Adult, Older Adult)",Phase 2,62.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",801,April 2008,December 2010,December 2010,"May 23, 2008",,"December 4, 2014","David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, United States|American Health Research, Charlotte, North Carolina, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Vermont Lung Center, University of Vermont, Burlington, Vermont, United States",134,,No Results Available,https://ClinicalTrials.gov/show/NCT00683722
NCT01510431,Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease,,Completed,Crohn's Disease,Drug: PROCHYMAL (remestemcel-L),Crohn's disease activity index (CDAI),"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,11.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRD 620,May 2009,September 2014,September 2014,"January 16, 2012",,"October 14, 2016","Unviersity of California, San Francisco, San Francisco, California, United States|Stormont-Vail, Topeka, Kansas, United States|Mount Sinai Hospital, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",135,,No Results Available,https://ClinicalTrials.gov/show/NCT01510431
NCT03678467,Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction,EB-CMF,Not yet recruiting,Mandible Tumor|Mandibular Injuries|Mandible; Deformity,Combination Product: EB-CMF,Number of participants with treatment-related adverse events|Bone regeneration as assessed by high-resolution CT scans|Quality of life as measured by the Glasgow Benefit Inventory,"Epibone, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,12.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EB-CMF-02,January 2020,August 2021,January 2022,"September 19, 2018",,"August 16, 2019","Cleveland Clinic, Cleveland, Ohio, United States",136,,No Results Available,https://ClinicalTrials.gov/show/NCT03678467
NCT02654925,Myeloid to Adipocyte Transdifferentiation in Human Cells,MYTH,Recruiting,Obesity,Procedure: Adipose Tissue Biopsy,"Adipogenic potential as measured by Oil Red-O staining (quantification by absorbance).|Adipocyte specific gene expression will be measured by qPCR (quantitative polymerase chain reaction) to confirm adipocyte status.|Assessment of the fraction of myeloid cells that become 'mesenchymal-like' (CD45-/CD14-/CD34+) (CD: cluster of differentiation) after fibrin culture by flow cytometry.|Progenitor cell proliferation capacity as measured by BrdU (bromodeoxyuridine) incorporation|In vivo adipogenesis in the Matrigel plug will be assessed by immunohistochemistry (IHC) for adipocyte (e.g., adiponectin) and nuclear markers (e.g., DAPI).","University of Colorado, Denver",All,"21 Years to 100 Years   (Adult, Older Adult)",,50.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Other,15-1779|UL1TR001082,March 2016,December 2019,December 2020,"January 13, 2016",,"October 16, 2018","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",137,,No Results Available,https://ClinicalTrials.gov/show/NCT02654925
NCT03169231,Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty,,Recruiting,Aging Frailty,Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo,Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo|Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo|Change in TNF-a compared to placebo,Longeveron LLC,All,70 Years to 85 Years   (Older Adult),Phase 2,150.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",001-03,"July 6, 2017","June 30, 2020","September 28, 2020","May 30, 2017",,"December 18, 2018","University of California, San Diego, La Jolla, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California, Irvine Senior Health Center, Orange, California, United States|Stanford University, Stanford, California, United States|Soffer Health Institute, Aventura, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|University of Florida-Institute on Aging, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Advanced Research for Health Improvement, LLC, Naples, Florida, United States",138,,No Results Available,https://ClinicalTrials.gov/show/NCT03169231
NCT00705120,Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation,,Completed,Osteogenesis Imperfecta,"Other: Bone Marrow Cell Transplantation|Radiation: Irradiation, Total Body|Drug: Cyclophosphamide|Drug: Cyclosporin|Procedure: Mesenchymal Stem Cell Transplantation|Drug: Busulfan",To investigate the safety and toxicity of allogeneic bone marrow transplantation (BMT) in children with severe Osteogenesis Imperfecta (OI),St. Jude Children's Research Hospital,All,"3 Years and older   (Child, Adult, Older Adult)",Phase 1,9.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOIT,November 1995,July 2000,October 2007,"June 25, 2008",,"June 25, 2008","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",139,,No Results Available,https://ClinicalTrials.gov/show/NCT00705120
NCT01557543,Stem Cell Injection to Treat Heart Damage During Open Heart Surgery,,Terminated,Heart Disease|Ischemic Heart Disease|Coronary Artery Disease|Coronary Artery Disease (CAD),Other: Cell Therapy,"To evaluate the safety and feasibility of direct intra-myocardial injection of autologous bone marrow stromal cells (BMSCs) in adult subjects undergoing coronary artery bypass graft (CABG) or transmyocardial revascularization (TMR).|To assess if direct intra-myocardial injection of autologous BMSCs improves the patient's cardiac function, quality of life, and reduces cardiac events compared to historical controls at three and six months after intervention.","National Heart, Lung, and Blood Institute (NHLBI)|NIH Heart Center at Suburban Hospital|National Institutes of Health Clinical Center (CC)",All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1,24.0,NIH|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,120078|12-H-0078,"February 29, 2012","July 25, 2017","June 18, 2018","March 19, 2012",,"July 4, 2018","Suburban Hospital, Bethesda, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",140,,No Results Available,https://ClinicalTrials.gov/show/NCT01557543
NCT00114452,Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction,,Completed,Myocardial Infarction,Drug: Provacel,"Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups.","Mesoblast International Sàrl|Mesoblast, Ltd.",All,"21 Years to 85 Years   (Adult, Older Adult)",Phase 1,53.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",401,February 2005,October 2006,February 2009,"June 15, 2005",,"December 4, 2014","Arizona Heart Institute, Phoenix, Arizona, United States|University of California - San Diego; Thornton, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|Rush University Medical Center, Chicago, Illinois, United States|The Care Group, Indianapolis, Indiana, United States|Jewish Hospital, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington Adventist, Takoma Park, Maryland, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Columbia Presbyterian Hospital, New York, New York, United States|University of Rochester - Strong Memorial, Rochester, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Austin Heart Institute, Austin, Texas, United States|Texas Medical School, Houston, Texas, United States",141,,No Results Available,https://ClinicalTrials.gov/show/NCT00114452
NCT00136903,Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute GVHD.,,Completed,Graft vs Host Disease,Drug: Prochymal - 2 million cells|Drug: Prochymal - 8 million cells,"Protocol 260 - Response by Day 28, also called Overall Response. Overall response. includes complete response (CR) and partial response (PR)|Protocol 261- Patients were followed for 2 years for safety. The incidence rate of different adverse events among subjects treated with either dose of Prochymal® in the preceding study (Protocol No. 260).|Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,|Protocol 260 - Time to best response of GVHD|Protocol 260 - Time to improvement of GVHD in one or more organs|Protocol 261 - Survival through study day 90",Osiris Therapeutics,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,33.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,260-261,February 2005,July 2008,July 2008,"August 29, 2005",,"September 4, 2009","St. Francis Hospital, Indianapolis, Indiana, United States|Kansas City Cancer Centers - BMT, Kansas City, Missouri, United States|The Cancer Center at Hackensack University, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, FEC, Milwaukee, Wisconsin, United States",142,,No Results Available,https://ClinicalTrials.gov/show/NCT00136903
NCT02501811,Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure,CONCERT-HF,"Active, not recruiting",Ischemic Cardiomyopathy,Biological: Mesenchymal Stem Cells (MSC)|Biological: c-kit+ cells|Biological: Placebo (Plasmalyte A),Change in Left Ventricular Ejection Fraction (LVEF) as measured by cMRI|Change in Global Strain (HARP MRI) as measured by cMRI|Change in Regional Strain (HARP MRI) as measured by cMRI|Change in Left Ventricular End Diastolic Volume Index (LVEDVI) as measured by cMRI|Change in Left Ventricular End Systolic Volume Index (LVESVI) as measured by cMRI|Change in Left Ventricular Sphericity Index as measured by cMRI|Change in Infarct/scar Volume (DEMRI) as measured by cMRI|Change in Maximal Oxygen Consumption (VO2 max) as measured by treadmill|Change in Exercise Tolerance as measured by the six minute walk test|Change in Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score|Cumulative Days alive and out of hospital for heart failure|Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured by blood draw|Incidence rate of Death|Incidence rate of Hospitalization for Heart Failure|Incidence rate of Heart Failure Exacerbation (Non hospitalization),"The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)",All,"21 Years to 79 Years   (Adult, Older Adult)",Phase 2,144.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-SPH-15-0413|5UM1HL087318,October 2015,November 2019,May 2020,"July 17, 2015",,"August 8, 2019","Stanford University School of Medicine (Falk Cardiovascular Research Center), Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdisciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States",143,,No Results Available,https://ClinicalTrials.gov/show/NCT02501811
NCT00361049,Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant,,Completed,Cancer,Biological: graft versus host disease prophylaxis/therapy|Genetic: fluorescence in situ hybridization|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: in vitro-treated bone marrow transplantation|Procedure: management of therapy complications,"Safety|Complete and partial resolution of graft-vs-host disease (GVHD)|Cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute GVHD",Case Comprehensive Cancer Center|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,49.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CWRU3Y03|P30CA043703|CASE-CWRU-3Y03,September 2004,June 2009,November 2010,"August 7, 2006",,"November 5, 2010","Geauga Regional Hospital, Cleveland, Ohio, United States|Lake/University Ireland Cancer Center, Cleveland, Ohio, United States|Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|University Suburban Health Center, Cleveland, Ohio, United States|UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States|Southwest General Health Center, Cleveland, Ohio, United States|UHHS Westlake Medical Center, Cleveland, Ohio, United States|Mercy Cancer Center at Mercy Medical Center, Cleveland, Ohio, United States",144,,No Results Available,https://ClinicalTrials.gov/show/NCT00361049
NCT02509156,Stem Cell Injection in Cancer Survivors,SENECA,"Active, not recruiting",Cardiomyopathy Due to Anthracyclines,Biological: Allo-MSCs|Biological: Placebo,Change in Left Ventricular Ejection Fraction (LVEF) as measured by cMRI|Change in Global Strain (HARP MRI) as measured by cMRI|Change in Regional Strain (HARP MRI) as measured by cMRI|Change in Left Ventricular End Diastolic Volume Index (LVEDVI) as measured by cMRI|Change in Left Ventricular End Systolic Volume Index (LVESVI) as measured by cMRI|Change in Left Ventricular Sphericity Index as measured by cMRI|Change in Area of Injury as measured by cMRI|Change in Exercise Tolerance as measured by the six minute walk test|Change in Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score|Cumulative Days Alive and Out of the Hospital|Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured by blood draw|Incidence rate of Death|Incidence rate of Hospitalization for Heart Failure|Incidence rate of Exacerbation of Heart Failure (Non hospitalization),"The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)",All,"18 Years to 79 Years   (Adult, Older Adult)",Phase 1,37.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC-SPH-15-0443|5UM1HL087318,August 2016,November 2019,August 2020,"July 27, 2015",,"June 27, 2019","Stanford University School of Medicine, Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdiciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States",145,"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/ICF_001.pdf",No Results Available,https://ClinicalTrials.gov/show/NCT02509156
NCT03838146,Influence of Maternal Exercise on Infant Skeletal Muscle and Metabolomics,,Recruiting,Exercise,Behavioral: Types of Exercise,"Human Skeletal Muscles cells grown from MSCs will have insulin responsiveness measured|Global and targeted metabolomics analysis will be conducted to map out pathways and mechanisms from regular maternal exercise. Docosahexaenoic acid (DHA), Eicosapentaenoic Acid (EPA), Docosapentaenoic Acid (DPA), and Arachidonic acid (ARA).|Peabody Developmental Motor Scales, 2nd edition (PDMS-2) will be performed by a pediatric physical therapist (blinded to group classification) to measure gross motor skills of infants up to 12 months of age.|A trained (blinded) researcher will measure bicep, tricep, and subscapular skinfold measures, circumferences (abdominal, head, mid-upper arm), and lengths (body, femur, leg, humeral). All measures are recorded as mm.|A trained (blinded) researcher will measure body weight on an infant scale",East Carolina University|American Heart Association,Female,18 Years to 35 Years   (Adult),Not Applicable,160.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention",12-002524b,"September 1, 2018","August 30, 2020","August 30, 2021","February 12, 2019",,"February 12, 2019","East Carolina University, Greenville, North Carolina, United States",146,,No Results Available,https://ClinicalTrials.gov/show/NCT03838146
NCT03856021,Microfracture vs. Microfracture and BMAC for Osteochondral Lesions of the Talus,,Enrolling by invitation,Osteochondral Lesion of Talus,Procedure: Microfracture with Bone Marrow Aspirate Concentrate|Procedure: Microfracture,Foot and Ankle Ability Measure (FAAM),Rothman Institute Orthopaedics,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RI2019Shakked,"October 18, 2018",October 2020,October 2020,"February 27, 2019",,"February 27, 2019","Rothman Institute, Philadelphia, Pennsylvania, United States",147,,No Results Available,https://ClinicalTrials.gov/show/NCT03856021
NCT03497780,Longitudinal Assessment of Cartilage Injury and Remodeling After Anterior Cruciate Ligament Rupture and Reconstruction:,,Recruiting,ACL - Anterior Cruciate Ligament Rupture|ACL Injury|Healthy,Procedure: Anterior cruciate ligament reconstruction,Change in Articular cartilage surface roughness|Change in Serum Cartilage Oligomeric Matrix Protein (COMP) concentration|Change in International Knee Documentation Committee (IKDC) score|Change in quantitative T2 mapping and T1rho mapping relaxation times from MRI.|Change in concentration of biomarkers of inflammation and cartilage metabolism.|Change in patient-reported outcome measures|Change in knee laxity,University of Michigan|Peking University Health Science Center,All,18 Years to 30 Years   (Adult),,38.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,HUM00137279,"February 1, 2018","February 1, 2020","February 1, 2021","April 13, 2018",,"April 12, 2019","University of Michigan, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States",148,,No Results Available,https://ClinicalTrials.gov/show/NCT03497780
NCT03688308,Bone Marrow Derived Stem Cells for the Treatment of Rotator Cuff Tears,,Recruiting,Rotator Cuff Tear|Rotator Cuff Injury,Procedure: Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Procedure: Arthroscopic rotator cuff repair,Tendon healing rates|UCLA Score|ASES Score|Constant Score|Retention of the mesenchymal stem cells,Stanford University,All,"50 Years to 75 Years   (Adult, Older Adult)",Not Applicable,80.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",IRB-47762,"March 27, 2019",October 2021,October 2021,"September 28, 2018",,"March 29, 2019","Stanford University, Redwood City, California, United States",149,,No Results Available,https://ClinicalTrials.gov/show/NCT03688308
NCT01061879,Expansion of Umbilical Cord Blood Using a Unique Bio-system,,Completed,Pregnancy,,bio-system for ex-vivo expansion of umbilical cord blood stem cells,University of Kansas|University of Kansas Medical Center,Female,"18 Years and older   (Adult, Older Adult)",,8.0,Other,Observational,,11973,February 2010,November 2010,November 2010,"February 3, 2010",,"January 3, 2013","University of Kansas Medical Center, Kansas City, Kansas, United States",150,,No Results Available,https://ClinicalTrials.gov/show/NCT01061879
NCT01152580,Melatonin Osteoporosis Prevention Study,MOPS,Completed,Osteoporosis|Osteopenia,Dietary Supplement: melatonin|Dietary Supplement: sugar pill,"The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Type-1 Collagen Cross-linked N-telopeptide (NTX) Levels in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Bone Density in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Physical Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Vasomotor Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Psychosocial Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Menopause-Specific Quality of Life (MENQOL) Sexual Domain Scores in Women After 6 Months, as Compared to Baseline.|The Effect of Melatonin (3 mg) or Placebo on the Mean Change in the Pittsburgh Sleep Quality Index (PSQI) in Women After 6 Months, as Compared to Baseline.",Duquesne University,Female,45 Years to 54 Years   (Adult),Phase 1,19.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",07-88,September 2008,July 2010,July 2010,"June 29, 2010","March 12, 2012","March 13, 2012","Duquesne University School of Pharmacy Center for Pharmacy Care, Pittsburgh, Pennsylvania, United States",151,,Has Results,https://ClinicalTrials.gov/show/NCT01152580
NCT00543374,Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease,,Completed,Crohn's Disease,Drug: Placebo|Drug: PROCHYMAL adult human mesenchymal stem cells,Duration of clinical benefit (Crohn's disease activity index)|Re-induction of clinical benefit (Crohn's disease activity index)|Improvement in quality of life (Inflammatory Bowel Disease Quality of Life assessment IBDQ instrument),"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,98.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRD 610,October 2007,July 2009,July 2009,"October 15, 2007",,"October 13, 2016","Advanced Clinical Research Institute, Anaheim, California, United States|Veteran's Administration Medical Center (does not require vet status), Long Beach, California, United States|University of Southern California University Hospital, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Western States Clinical Research, Wheat Ridge, Colorado, United States|Gastroenterology Center of Connecticut, Hamden, Connecticut, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Venture Research Institute, Miami, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Carle Clinic Association, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Gulf Coast Research, Baton Rouge, Louisiana, United States|National Institutes of Health, Bethesda, Maryland, United States|Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Center for Clinical Studies, Dearborn, Michigan, United States|Center for Digestive Health, Troy, Michigan, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|St Louis Center for Clinical Studies, St Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Gastroenterology Research Associates, Cedar Knolls, New Jersey, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Rochester Institute for Digestive Diseases, Rochester, New York, United States|Rochester General Hospital, Rochester, New York, United States|University Hospital and Medical Center, Stony Brook, New York, United States|Charlotte Gastroenterology and Hepatology, Charlotte, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Dayton Science Institute, Dayton, Ohio, United States|Gastroenterology United of Tulsa, Tulsa, Oklahoma, United States|Options Health Research, Tulsa, Oklahoma, United States|Allegheney Center for Digestive Health, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Gastroenterology Center of the Midsouth, Germantown, Tennessee, United States|Nashville GI Specialists, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Memorial Hermann Hospital, Houston, Texas, United States|University of Vermont, Burlington, Vermont, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|McGuire Research Institute, Richmond, Virginia, United States|Seattle Gastroenterology Associates, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada",152,,No Results Available,https://ClinicalTrials.gov/show/NCT00543374
NCT00690066,PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM),,Completed,"Type 1 Diabetes Mellitus|Type 1 Diabetes|Diabetes Mellitus, Insulin-Dependent|Juvenile Diabetes",Drug: PROCHYMAL®|Drug: Placebo,C-peptide AUC response (MMTT)|Peak C-peptide response (MMTT)|Basal C-peptide response|Total daily insulin dose (units/kg)|Glycosylated hemoglobin (HbA1c) levels|Number of severe and documented hypoglycemic events|Changes in levels of GAD or IA-2 autoantibodies,"Mesoblast International Sàrl|Juvenile Diabetes Research Foundation|Mesoblast, Ltd.",All,"12 Years to 35 Years   (Child, Adult)",Phase 2,63.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",901,June 2008,December 2010,December 2011,"June 4, 2008",,"December 4, 2014","University of Alabama, Division of Endocrinology & Metabolism, Birmingham, Alabama, United States|Scripps Whittier Diabetes Institute, LaJolla, California, United States|Stanford University, Stanford, California, United States|University of Florida, Gainesville, Florida, United States|Diabetes Research Institute, Miami, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University of Minnesota, Minneapolis, Minnesota, United States|Desert Endocrinology CRC, Henderson, Nevada, United States|Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States|University of North Carolina Diabetes Care Center, Chapel Hill, North Carolina, United States|American Health Research, Inc., Charlotte, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Providence Health Partners - Center for Clinical Research, Dayton, Ohio, United States|Cumberland Valley Endocrinology, Carlisle, Pennsylvania, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|The Strelitz Diabetes Center, Eastern VA Medical School, Norfolk, Virginia, United States|University of Wisconsin Health- West Clinic, Madison, Wisconsin, United States|Clinical and Transitional Science Institute, Milwaukee, Wisconsin, United States",153,,No Results Available,https://ClinicalTrials.gov/show/NCT00690066
NCT00482092,Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease,,"Active, not recruiting",Crohn's Disease,Drug: adult human mesenchymal stem cells|Drug: Placebo,Disease remission (CDAI at or below 150)|Disease improvement (Reduction by at least 100 points in CDAI)|Improvement in quality of life (IBDQ)|Reduction in number of draining fistulas,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,330.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CRD 603,May 2007,July 2018,July 2020,"June 4, 2007",,"December 8, 2017","University of Southern California University Hospital, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Western States Clinical Research, Wheat Ridge, Colorado, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Carle Clinic Association, Urbana, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Gulf Coast Research, Baton Rouge, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|National Institutes of Health, Bethesda, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Center for Clinical Studies, Dearborn, Michigan, United States|Center for Digestive Health, Troy, Michigan, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|St Louis Center for Clinical Studies, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Rochester Institute for Digestive Diseases, Rochester, New York, United States|Rochester General Hospital, Rochester, New York, United States|University Hospital and Medical Center, Stony Brook, New York, United States|Charlotte Gastroenterology and Hepatology, Charlotte, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Gastroenterology United of Tulsa, Tulsa, Oklahoma, United States|Options Health Research, Tulsa, Oklahoma, United States|Allegheney Center for Digestive Health, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Gastroenterology Center of the Midsouth, Germantown, Tennessee, United States|Nashville GI Specialists, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|University of Vermont, Burlington, Vermont, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|McGuire Research Institute, Richmond, Virginia, United States|Seattle Gastroenterology Associates, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Health Science Centre, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|University of Otago, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand",154,,No Results Available,https://ClinicalTrials.gov/show/NCT00482092
NCT03467919,Adipose-Derived Stem Cell Injections for Knee Osteoarthritis,,Recruiting,"Osteoarthritis, Knee|Knee Pain",Procedure: Stem Cell injection|Procedure: Corticosteroid injection,Knee Injury and Osteoarthritis Outcomes Score (KOOS) Score|Lysholm score|Veterans RAND 12 (VR-12) score,Stanford University,All,"35 Years to 75 Years   (Adult, Older Adult)",Phase 3,40.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",41688,"April 1, 2018",June 2020,June 2020,"March 16, 2018",,"September 24, 2019","Stanford University, Stanford, California, United States",155,,No Results Available,https://ClinicalTrials.gov/show/NCT03467919
NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients,,Recruiting,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn® (MSC-NTF cells)|Other: Placebo,To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,18 Years to 60 Years   (Adult),Phase 3,200.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,"August 28, 2017","July 30, 2019","July 30, 2020","September 12, 2017",,"July 8, 2019","University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",156,,No Results Available,https://ClinicalTrials.gov/show/NCT03280056
NCT00877903,Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI),,Completed,Myocardial Infarction,Drug: Prochymal®|Drug: Placebo,Left ventricular end systolic volume|Infarct size|Left ventricular ejection fraction|Left ventricular end diastolic volume|Incidence of ventricular arrhythmias|Cardiovascular disease-specific quality of life (DASI) assessment|NYHA congestive heart failure classification status|Maximal symptom-limited exercise test (treadmill)|MACE endpoints|Survival Status|Adverse Event,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"21 Years to 85 Years   (Adult, Older Adult)",Phase 2,220.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",403,March 2009,December 2011,August 2016,"April 8, 2009",,"March 22, 2018","Mercy Gilbert Medical Center / Catholic Health Care West, Gilbert, Arizona, United States|University of Arizona, Tucson, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|University of California - San Diego (UCSD), San Diego, California, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The Care Group, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Maryland Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University at Buffalo - Buffalo General Hospital, Buffalo, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Lindner Research Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State University - Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|The Stern Cardiovascular Center, Germantown, Tennessee, United States|Austin Heart P.A., Austin, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|University of Wisconsin School of Medicine, Madison, Wisconsin, United States|McGill University Health Centre, Montreal, Quebec, Canada",157,,No Results Available,https://ClinicalTrials.gov/show/NCT00877903
NCT02467387,A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure,,Unknown status,Non-Ischemic Heart Failure,Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Drug: Lactated Ringer's Solution,"Safety will be evaluated by the incidence, severity, and relationship of AEs and SAEs|Change in LVEF from baseline to day 90 post-initial infusion. After crossover phase all subjects will be evaluated for changes from the new baseline (Day 90 after initial infusion) to Day 90 post second infusion.","CardioCell LLC|Stemedica Cell Technologies, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,23.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,STEM-104-M-CHF,June 2014,April 2017,April 2017,"June 10, 2015",,"April 20, 2016","MedStar Washington Hospital Center, Washington, District of Columbia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwestern University Centers for Heart Failure Therapy, Chicago, Illinois, United States|Stony Brook Heart Institute, Stony Brook, New York, United States|Hospital of the University of Pennsylvania, Heart Failure and Transplant Program, Philedelphia, Pennsylvania, United States",158,,No Results Available,https://ClinicalTrials.gov/show/NCT02467387
NCT01805388,Comparison of Tissue in Regenerative Endodontic Procedures and Apexification,,Withdrawn,Dental Pulp Regeneration,Drug: Experimental: Regeneration Treatment Group|Procedure: Control Non-Study Drug Group,Histological identification of the mineralized tissue at the apical third of the root and the adherent cellular layer.|Whether stem cells enter the canal space when bleeding is stimulated through manipulation of the apical papilla.,Kenneth Hargreaves|The University of Texas Health Science Center at San Antonio,All,"9 Years to 18 Years   (Child, Adult)",Phase 1,0.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,HSC20130054H,February 2013,October 2015,October 2015,"March 6, 2013",,"February 5, 2016","University of Texas Health Science Center, San Antonio, Texas, United States",159,,No Results Available,https://ClinicalTrials.gov/show/NCT01805388
NCT03015623,A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy,,Recruiting,Acute Kidney Injury,Biological: SBI-101|Device: Sham,Safety and tolerability as measured by incidence of IP-related serious adverse events,"Sentien Biotechnologies, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,24.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SBI-101-01,"June 20, 2017",December 2018,December 2018,"January 10, 2017",,"September 6, 2018","Lehigh Valley Hospital, Allentown, Pennsylvania, United States",160,,No Results Available,https://ClinicalTrials.gov/show/NCT03015623
NCT00759018,Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD,,No longer available,Graft vs Host Disease|Graft-Versus-Host Disease,Biological: remestemcel-L,,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,2 Months to 17 Years   (Child),,,Industry,Expanded Access,,275,,,,"September 25, 2008",,"July 12, 2018","Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF, San Francisco, California, United States|Children's National, Washington, District of Columbia, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Childrens Memorial, Chicago, Illinois, United States|James Witcomb Riley Hosptial for Children, Indianapolis, Indiana, United States|LSU Health Science Center/Children's Hospital, New Orleans, Louisiana, United States|Wayne State University/Childrens' Hospital, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Doernbecher Children's Hospital (OHSU), Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|Texas Childrens Hospital, Houston, Texas, United States|Methodist Childrens Hospital of South Texas, San Antonio, Texas, United States|Massey Cancer Center, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|Montreal Children's Hospital, Montreal, Quebec, Canada|CHU Sainte-Justine, Montreal, Quebec, Canada",161,,No Results Available,https://ClinicalTrials.gov/show/NCT00759018
NCT02926079,Investigation of Mechanisms for Transmission of Impaired Glucose Metabolism in Infants Exposed to Diabetes in Utero,IMAGINE,Completed,Pregnancy|Gestational Diabetes Mellitus,,Metabolic flexibility - Mother|Metabolic Flexibility - Infant|Lipid content in placenta samples|Mitochondrial oxygen consumption rates in placenta samples|Fat content in umbilical cord mesenchymal stem cells|Oxygen consumption rates in umbilical cord mesenchymal stem cells,"Pennington Biomedical Research Center|University of Colorado, Denver",Female,18 Years to 40 Years   (Adult),,18.0,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,PBRC 2016-071,"May 23, 2017","November 8, 2018","January 8, 2019","October 6, 2016",,"June 10, 2019","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",162,,No Results Available,https://ClinicalTrials.gov/show/NCT02926079
NCT01071577,Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products,,Completed,Bone Marrow Stromal Cells,,Tissue Collection,National Institutes of Health Clinical Center (CC),All,"18 Years to 100 Years   (Adult, Older Adult)",,65.0,NIH,Observational,Observational Model: Other|Time Perspective: Prospective,100053|10-CC-0053,"January 27, 2010",,,"February 19, 2010",,"October 10, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",163,,No Results Available,https://ClinicalTrials.gov/show/NCT01071577
NCT02886884,Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects,ACESO,"Active, not recruiting",Diabetes Mellitus,Drug: 20 million Allogeneic Mesenchymal Human Stem Cells|Drug: 100 million Allogeneic Mesenchymal Human Stem Cells,Assess treatment-emergent serious adverse events|Assess Endothelial Progenitor cell - colony forming units|Assess circulating inflammatory markers (IL-1)|Assess circulating inflammatory markers (IL-6)|Assess circulating inflammatory markers (Tumor Necrosis Factor(TNF) alpha)|Assess circulating inflammatory markers (CRP)|Assess circulating angiogenic factors|Assess Stromal cell derived factor (SDF)-1 alpha|Assess Vascular endothelial growth factor (VEGF)|Assess stem cell factor (SCF)|Assess FMD%,"Ivonne Schulman|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami",All,"21 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,10.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20160686|1R01HL134558-01,"October 20, 2017",September 2023,September 2024,"September 1, 2016",,"September 5, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States",164,,No Results Available,https://ClinicalTrials.gov/show/NCT02886884
NCT03096782,Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma,,"Active, not recruiting","Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chemotherapy-Related Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Langerhans Cell Histiocytosis|Minimal Residual Disease|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Myelodysplastic Syndrome|Small Lymphocytic Lymphoma|Therapy-Related Myelodysplastic Syndrome",Biological: Anti-Thymocyte Globulin|Drug: Busulfan|Drug: Clofarabine|Drug: Cyclophosphamide|Biological: Filgrastim-sndz|Drug: Fludarabine|Drug: Melphalan|Drug: Mycophenolate Mofetil|Biological: Rituximab|Drug: Tacrolimus|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation,Feasibility of cord blood infusion|Time to engraftment|Disease-free survival|Overall survival|Treatment-related mortality (TRM),M.D. Anderson Cancer Center|National Cancer Institute (NCI),All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 2,25.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016-0051|NCI-2018-01236|P30CA016672,"October 13, 2017","October 31, 2020","October 31, 2020","March 30, 2017",,"May 22, 2019","M D Anderson Cancer Center, Houston, Texas, United States",165,,No Results Available,https://ClinicalTrials.gov/show/NCT03096782
NCT00225095,A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy,,Completed,Recovery Following Partial Medial Meniscectomy,Drug: Mesenchymal Stem Cells|Drug: Hyaluronan,meniscal volume|quality of life|immunological endpoints|Safety,"Mesoblast International Sàrl|University of Southern California|Midwest Orthopedics at Rush - Chicago, IL|Unlimited Research - San Antonio, TX|Triangle Orthopaedic Associates, P.A.|Orthopedic Center of Vero Beach - Vero Beach, FL|OrthoIndy|TRIA Orthopaedic Center|Greater Chesapeake Orthopaedic Associates, LLC|Mesoblast, Ltd.",All,18 Years to 60 Years   (Adult),Phase 1|Phase 2,55.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Osiris 550,September 2005,April 2008,April 2008,"September 23, 2005",,"December 4, 2014","University of Southern California, Los Angeles, California, United States|Orthopedic Center of Vero Beach, Vero Beach, Florida, United States|Midwest Orthopaedics at Rush, Chicago, Illinois, United States|Ortholndy, Indianapolis, Indiana, United States|Greater Chesapeake Associates, Baltimore, Maryland, United States|TRIA Orthopaedic Center, Bloomington, Minnesota, United States|Triangle Orthopaedics Associates, P.A., Durham, North Carolina, United States|Unlimited Research, San Antonio, Texas, United States",166,,No Results Available,https://ClinicalTrials.gov/show/NCT00225095
NCT01233960,Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease,,"Active, not recruiting",Crohn's Disease,Drug: adult human mesenchymal stem cells,Disease remission|Disease Improvement|Improvement in Quality of Life (IBDQ)|Number of Adverse events as a measure of safety|Infusional toxicity as a measure of safety and tolerability,"Mesoblast International Sàrl|Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,120.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CRD 611,September 2010,February 2019,February 2019,"November 3, 2010",,"December 11, 2017","University of California, San Francisco, San Francisco, California, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|University of Chicago, Chicago, Illinois, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Saint Louis Center for Clinical Research, Saint Louis, Missouri, United States|St. Louis Center for Clinical Studies, Saint Louis, Missouri, United States|Dartmouth HItchcock Medical Center, Lebanon, New Hampshire, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Gastroenterology Center of the Midsouth, PC, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|McGuire Research Institute, Richmond, Virginia, United States|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|University of Otago, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand",167,,No Results Available,https://ClinicalTrials.gov/show/NCT01233960
NCT00927355,Effect of Thiazolidinediones on Human Bone,,Completed,Osteoblast|Adipocytes|Bone Density|Osteocalcin|Adiponectin|Mesenchymal Stem Cells,Drug: Pioglitazone|Drug: Placebo,"Percent Change in Number of Osteoblast and Adipocyte Colony Forming Units Cultured From Bone Marrow Stem Cells Harvested 6 Months After Treatment With Study Drug Compared to Baseline|βCTX (Carboxy Terminal Collagen Crosslinks), Osteocalcin, and Adiponectin.|Bone Mineral Density",Emory University,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,10.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)",IRB00014509|08006,April 2009,October 2010,July 2011,"June 25, 2009","June 2, 2014","March 29, 2016","Grady Diabetes Clinic, Atlanta, Georgia, United States",168,,Has Results,https://ClinicalTrials.gov/show/NCT00927355
NCT00988338,Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion,TAF,Completed,"Tibiotalar Arthrodesis|Subtalar Arthrodesis|Calcaneocuboid Arthrodesis|Talonavicular Arthrodesis|Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular)|Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)",Biological: Trinity Evolution,"Fusion Success|Improvement in scores: Ankle-Hindfoot Scale (AHS), Visual Analog Scale (VAS), and Health Survey (SF-36v2).",Orthofix Inc.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,106.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TY01AF,September 2009,January 2013,January 2013,"October 2, 2009",,"April 8, 2014","Orthopaedic Associates of South Broward, PA, Hollywood, Florida, United States|Sinai Hospital of Baltimore / Rubin Institute for Advanced Orthopedics, Baltimore, Maryland, United States|New Mexico Orthopedics, Albuquerque, New Mexico, United States|OrthoCarolina Research Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio Orthopedic Center of Excellence, Upper Arlington, Ohio, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|Central Tennessee Foot and Ankle Center, Sparta, Tennessee, United States|Franciscan Foot and Ankle Specialists, Burien, Washington, United States",169,,No Results Available,https://ClinicalTrials.gov/show/NCT00988338
NCT01297413,A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke,,Completed,Ischemic Stroke,Biological: Allogeneic adult mesenchymal bone marrow stem cells,The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.|National Institutes of Health Stroke Scale Score.|Mini Mental Status Exam score.|Barthel Index Score.|The Geriatric Depression Scale Score.,"Stemedica Cell Technologies, Inc.|University of California, San Diego|Mercy Gilbert Medical Center at AZ|Chandler Regional Medical Center at Chandler AZ|UCI Medical Center",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,38.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STEM 101-M,February 2011,September 2017,"November 15, 2018","February 16, 2011",,"December 3, 2018","Mercy Gilbert and Chandler Medical Center, Gilbert, Arizona, United States|University of California Irvine Department of Neurology, Orange, California, United States|University of California San Diego Division of Neurological Surgery, San Diego, California, United States",170,,No Results Available,https://ClinicalTrials.gov/show/NCT01297413
NCT00815217,The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers,,Unknown status,Diabetic Wounds|Venous Stasis Wounds,Procedure: injection of lipoaspirate|Other: control,"wound measurements, healing of wounds, pictures of wounds",Washington D.C. Veterans Affairs Medical Center,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,250.0,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,01194,February 2009,February 2010,February 2010,"December 29, 2008",,"December 29, 2008","Veterans Affairs Medical Center, Washington D.C., Washington D.C., District of Columbia, United States",171,,No Results Available,https://ClinicalTrials.gov/show/NCT00815217
NCT03197623,Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids,,"Active, not recruiting",Osteopenia|Osteoporosis|Osteonecrosis,Drug: LLP2A-ALENDRONATE|Drug: Placebo,Dose limiting Adverse events|Severe infusion reactions|Grade 2 elevated creatinine,"Nancy E. Lane, MD|California Institute for Regenerative Medicine (CIRM)|University of California, Davis",All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 1,50.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20161825|LLP2A-001,"October 14, 2016",January 2020,June 2020,"June 23, 2017",,"June 14, 2019","West Coast Clinical Trials (WCCT), Cypress, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Metroplex Clinical Research Center, Dallas, Texas, United States",172,,No Results Available,https://ClinicalTrials.gov/show/NCT03197623
NCT03529877,Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa,,Recruiting,Recessive Dystrophic Epidermolysis Bullosa,Biological: allo-APZ2-EB,"Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score), score), or last available post-baseline measurement if the Week 12 measurement is missing|Assessment of adverse event (AE) occurrence|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)|Inflammation (measured by panel of inflammation markers)|Pain assessment as per NRS|Itch assessment as per NRS|Differences in patient's quality of life in EB|Physical examination until Week 12;|Vital signs: Body temperature until Week 12;|Vital signs: Blood pressure until Week 12;|Vital signs: Heart rate until Week 12;|Overall survival at month 24",RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Granzer Regulatory Consulting & Services|Ticeba GmbH,All,"12 Months to 55 Years   (Child, Adult)",Phase 1|Phase 2,18.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,allo-APZ2-EB-II-01,"January 16, 2019",January 2022,January 2022,"May 18, 2018",,"September 17, 2019","University of Minnesota, Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States|EB-Haus Austria; Salzburger Landeskliniken (SALK); Paracelsus Medizinische Privatuniversität Salzburg (PMU), Salzburg, Austria|Hôpital Saint-Louis; Département de dermatologie, Paris, France|Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany|IRCCS Ospedale Pediatrico Bambino Gesù; Dipartimento di Medicina Pediatrica - U.O.C. di Dermatologia, Roma, Italy|King's College London; St John's Institute of Dermatology;, London, United Kingdom|Great Ormond Street Hospital; Dermatology Department, London, United Kingdom",173,,No Results Available,https://ClinicalTrials.gov/show/NCT03529877
NCT00081055,OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies,,Withdrawn,Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes,Biological: autologous expanded mesenchymal stem cells OTI-010|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,"Incidence of acute GVHD grade II-IV of skin, liver and gut (stomach to rectum) through Day 84 post-PBSC transplantation|Safety as measured by infusional toxicity, relapse nd survival, formation of potential ectopic tissue foci","Mesoblast International Sàrl|National Cancer Institute (NCI)|Mesoblast, Ltd.",All,18 Years to 55 Years   (Adult),Phase 2,0.0,Industry|NIH,Interventional,Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care,Mesoblast|UCLA-0303036|CDR0000358809,,,,"April 8, 2004",,"December 4, 2014","Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States",174,,No Results Available,https://ClinicalTrials.gov/show/NCT00081055
NCT02807389,Stem Cell Fistula Plug in Post Surgical Leak Fistulas,,Completed,Surgical Leak Fistula,Drug: MSC Fistula Plug,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Fistula Closure,Mayo Clinic,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,2.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-004326,"March 14, 2017","April 2, 2019","April 2, 2019","June 21, 2016",,"April 23, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",175,,No Results Available,https://ClinicalTrials.gov/show/NCT02807389
NCT01920867,Stem Cell Ophthalmology Treatment Study,SCOTS,Enrolling by invitation,Retinal Disease|Macular Degeneration|Hereditary Retinal Dystrophy|Optic Nerve Disease|Glaucoma,Procedure: RB (Retrobulbar)|Procedure: ST (Subtenon)|Procedure: IV (Intravenous)|Procedure: IVIT (Intravitreal)|Procedure: IO (Intraocular),Visual acuity|Visual fields,MD Stem Cells,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,300.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ICMS-2013-0019.,August 2013,August 2018,August 2019,"August 12, 2013",,"August 27, 2019","MD Stem Cells, Westport, Connecticut, United States",176,,No Results Available,https://ClinicalTrials.gov/show/NCT01920867
NCT01739504,Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.,,Terminated,Osteoarthritis,Procedure: Liposuction with Local Anesthesia|Biological: Intra articular infusion of AD-SVF,"Change from Baseline in Visual Analogue Scale (VAS)|Change from Baseline of Quality of life scores|Change from Baseline of Reduction in analgesics|Number of adverse events reported|Change from Baseline in x-ray, sonogram, or MRI imaging of affected joint compared to baseline.",Ageless Regenerative Institute,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,10.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AD-US-OR-001,"March 1, 2014","April 1, 2017","April 1, 2017","December 3, 2012",,"November 24, 2017","Ageless Institute LLC, Aventura, Florida, United States",177,,No Results Available,https://ClinicalTrials.gov/show/NCT01739504
NCT03220243,Stem Cell Coated Fistula Plug in Patients With Crohn's RVF,,"Active, not recruiting",Fistula Vagina|Crohn Disease,Drug: MSC-AFP,Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.,Mayo Clinic,Female,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,5.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-002892,"October 19, 2017","July 20, 2020","December 20, 2020","July 18, 2017",,"August 7, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",178,,No Results Available,https://ClinicalTrials.gov/show/NCT03220243
NCT01413061,Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft,,Completed,Degenerative Osteoarthritis|Post-traumatic; Arthrosis|Rheumatoid Arthritis & Other Inflammatory Polyarthropathies|Rheumatoid Arthritis of Subtalar Joint,Procedure: Subtalar Arthrodesis,Fusion Rate (%)(as determined by CT assessment)|Radiographic outcome assessments|Functional outcome measurements,AlloSource,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,140.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AlloSource Subtalar Fusion RCT,June 2010,February 2017,March 2018,"August 10, 2011",,"April 13, 2018","Institute for Foot and Ankle Reconstruction at Mercy, Baltimore, Maryland, United States|Orthopaedic Associates of Michigan, Grand Rapids, Michigan, United States|Minnesota Orthopedic Sports Medicine Institute (MOSMI), Edina, Minnesota, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Campbell Clinic, Germantown, Tennessee, United States",179,,No Results Available,https://ClinicalTrials.gov/show/NCT01413061
NCT03011541,Stem Cell Ophthalmology Treatment Study II,SCOTS2,Recruiting,"Retinal Disease|Age-Related Macular Degeneration|Retinitis Pigmentosa|Stargardt Disease|Optic Neuropathy|Nonarteritic Ischemic Optic Neuropathy|Optic Atrophy|Optic Nerve Disease|Glaucoma|Leber Hereditary Optic Neuropathy|Blindness|Vision Loss Night|Vision Loss Partial|Vision, Low|Retinopathy|Maculopathy|Macular Degeneration|Retina Atrophy",Procedure: Arm 1|Procedure: Arm 2|Procedure: Arm 3,Visual Acuity|Visual Fields|Optical Coherence Tomography (OCT),MD Stem Cells,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,500.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SCOTS2,January 2016,January 2020,January 2021,"January 5, 2017",,"August 28, 2019","MD Stem Cells, Westport, Connecticut, United States|MD Stem Cells, Coral Springs, Florida, United States",180,,No Results Available,https://ClinicalTrials.gov/show/NCT03011541
NCT02802384,Pathophysiology of Paget's Disease of Bone,,Recruiting,Paget's Disease of Bone,,Serum chemokine level|Correlation of chemokine level to Paget's Disease of Bone Pain|Correlation of chemokine level to alkaline phosphatase concentration|Correlation of chemokine level to proportion of affected skeleton|Correlation of chemokine level to number of circulating stem cells,Johns Hopkins University,All,"18 Years to 99 Years   (Adult, Older Adult)",,20.0,Other,Observational,Observational Model: Case-Control|Time Perspective: Cross-Sectional,IRB00077130,April 2016,April 2022,June 2022,"June 16, 2016",,"June 12, 2019","Johns Hopkins University, Baltimore, Maryland, United States",181,,No Results Available,https://ClinicalTrials.gov/show/NCT02802384
NCT03079401,Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle,,Recruiting,Hypoplastic Left Heart Syndrome|Atrioventricular Canal,Biological: MPC; rexlemestrocel-L,Safety- Incidence of severe adverse events|Safety- Absence of PRA status change or local inflammation|Efficacy- rate of biventricular conversion|Efficacy- improvement of LV end diastolic pressure|Efficacy- improvement of LV mass/volume ratio,Boston Children’s Hospital,All,up to 5 Years   (Child),Phase 1|Phase 2,24.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",IRB-P00020575,"November 27, 2017",November 2020,November 2021,"March 14, 2017",,"January 30, 2019","Boston Children's Hospital, Boston, Massachusetts, United States",182,,No Results Available,https://ClinicalTrials.gov/show/NCT03079401
NCT02589119,Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP),,"Active, not recruiting",Perianal Fistula|Cryptoglandular Perianal Fistula,Drug: MSC-AFP,Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.,Mayo Clinic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,15.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,15-003200,January 2016,October 2019,November 2019,"October 28, 2015",,"August 7, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",183,,No Results Available,https://ClinicalTrials.gov/show/NCT02589119
NCT01602328,A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects,ACT-AKI,Terminated,Acute Kidney Injury,Biological: AC607|Biological: Vehicle Only,Time to Kidney Recovery defined as a post-operative serum creatinine return to pre-operative baseline values.|All-Cause Mortality or Dialysis (composite endpoint).,AlloCure Inc.,All,"21 Years and older   (Adult, Older Adult)",Phase 2,156.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AC 6071103,June 2012,June 2014,August 2014,"May 21, 2012",,"August 6, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California, San Diego, San Diego, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|Maine Medical Center, Portland, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|UTHealth, The University of Texas Health Science Center at Houston, Houston, Texas, United States|Fletcher Allen Health Care - Renal Services, Burlington, Vermont, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|CAMC Clinical Trials Center, Charleston, West Virginia, United States|Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|University of Manitoba - St. Boniface Hospital, Winnipeg, Manitoba, Canada|CDHA Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|McMaster - Hamilton General Hospital / TAARI, Hamilton, Ontario, Canada|London Health Sciences Centre, University Hospital, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada",184,,No Results Available,https://ClinicalTrials.gov/show/NCT01602328
NCT01915927,Stem Cell Fistula Plug in Perianal Crohn's Disease,MSC-AFP,"Active, not recruiting",Perianal Crohn's Disease,Drug: MSC-AFP,To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.|To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC,"William A. Faubion, M.D.|Mayo Clinic",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12-009716,July 2013,November 2019,March 2020,"August 5, 2013",,"August 7, 2019","Mayo Clinic, Rochester, Minnesota, United States",185,,No Results Available,https://ClinicalTrials.gov/show/NCT01915927
NCT03608579,Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA,,Recruiting,"Osteoarthritis, Hip",Drug: Autologous Adipose Derived Mesenchymal Stromal Cells,"Nature, incidence and severity of adverse events (AEs)|Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles|Change in Tegner activity scale in the target hip following completion of treatment cycles|Change in modified Harris Hip Score (mHHS) in the target hip following completion of treatment cycles|Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles|Change in radiographic joint morphology|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Change periarticular soft-tissues|Change in synovial fluid biomarkers within the target hip",Mayo Clinic,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,24.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-000015,"November 5, 2018","December 31, 2021","December 31, 2021","August 1, 2018",,"October 11, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",186,,No Results Available,https://ClinicalTrials.gov/show/NCT03608579
NCT02525432,Autologous Stem Cell Study for Adult TBI (Phase 2b),,Enrolling by invitation,"Brain Injuries, Traumatic|Brain Injuries, Acute|TBI (Traumatic Brain Injury)",Biological: Placebo Infusion|Biological: Autologous BMMNC Infusion,Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.|Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.|Compare neuro-inflammatory biomarkers between groups..|Measure the number of participants with infusion related adverse events.|Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.|Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).|Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.|Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.,"The University of Texas Health Science Center, Houston|United States Department of Defense|U.S. Army Medical Research and Development Command",All,18 Years to 55 Years   (Adult),Phase 2,55.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",HSC-MS-16-0283,"November 21, 2016",October 2020,December 2020,"August 17, 2015",,"August 13, 2019","The University of Texas Health Science Center at Houston, Houston, Texas, United States",187,,No Results Available,https://ClinicalTrials.gov/show/NCT02525432
NCT03449069,Pediatric MSC-AFP Sub-study for Crohn's Fistula,,Recruiting,Fistula in Ano|Crohn Disease,Drug: MSC-AFP,Number of participants with treatment-related adverse events (safety and toxicity)|Number of participants with response to the treatment regarding cessation of drainage from the treated fistula.|Number of participants with radiographic response to the treatment regarding the treated fistula.,Mayo Clinic,All,12 Years to 17 Years   (Child),Phase 1,5.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,17-010539,"July 23, 2018","February 28, 2020","February 28, 2021","February 28, 2018",,"August 7, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",188,,No Results Available,https://ClinicalTrials.gov/show/NCT03449069
NCT00957931,"Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs",,Completed,Sickle Cell Disease|Thalassemia|Diamond-Blackfan Anemia,Procedure: Bone marrow transplantation|Biological: Mesenchymal Stromal Cells,Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)|Overall Survival 6 Months Following HCT|Overall Survival 1 Year Following HCT|Count of Participants With Disease-free Survival 6 Months Following HCT|Count of Participants With Disease-free Survival 1 Year Following HCT,Stanford University|University of Minnesota - Clinical and Translational Science Institute|University of Alabama at Birmingham,All,"1 Year to 25 Years   (Child, Adult)",Phase 2,6.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSC01,March 2009,August 2013,August 2013,"August 13, 2009","August 6, 2018","August 6, 2018","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Minnesota, Minneapolis, Minnesota, United States",189,,Has Results,https://ClinicalTrials.gov/show/NCT00957931
NCT01460901,"Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma",STALLONe,Completed,Neuroblastoma,Biological: GD2 CAR modified Tri-virus specific cytotoxic t-cells,Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks|Peak Transgene Copy Number Per 1000ng PBMC DNA|Death Within 8 Weeks of Infusion|Peak Viral Specific SFU/2x10e5 Mononuclear Cells Per Well|Maximum Tumor Response (RECIST 1.1),"Children's Mercy Hospital Kansas City|Center for Cell and Gene Therapy, Baylor College of Medicine",All,18 Months to 17 Years   (Child),Phase 1,5.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STALLONe|00038,October 2012,January 2015,January 2015,"October 27, 2011","July 23, 2019","July 23, 2019","Children's Mercy Hospital, Kansas City, Missouri, United States",190,,Has Results,https://ClinicalTrials.gov/show/NCT01460901
NCT02052908,Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome,,"Active, not recruiting",Lynch Syndrome,Other: Laboratory Biomarker Analysis|Drug: Naproxen|Other: Placebo,"Change in PGE2 concentration levels in normal colorectal mucosa|Minimal biologically effective dose of naproxen that induces a modulation of PGE2 levels|Incidence of toxicity|Naproxen concentrations in plasma samples|Naproxen concentrations in normal colorectal mucosa|PGE-M levels in urine samples|Change in number of polyps observed in the rectosigmoid area|Changes in the microRNA profile of the normal colorectal mucosa|Changes in gene expression mRNA profiles of the normal colorectal mucosa|Changes in the mutational rate of the normal colorectal mucosa|Changes in the microbiome of the normal colorectal mucosa|Changes in the PGF2, PGD2, Thromboxane B2, 9a11b-PGF2a and 6-KetoPGF1a levels of the colorectal tissue|Changes in the stem cell and epithelial differentiation marker levels|Changes in the number and type of immune and mesenchymal cells recruited to the colorectal mucosa",National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1,81.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",NCI-2014-00046|N01-CN-2012-00034|HHSN261201200034I|HUM00079757|HHSN26100003; RFP B|MDACC IRB # 2013-0698|2013-0698|13-585|MDA2013-01-02|N01CN00034|P30CA016672,"January 27, 2014","October 25, 2017",,"February 3, 2014",,"October 15, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|M D Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",191,,No Results Available,https://ClinicalTrials.gov/show/NCT02052908
NCT02688114,Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus,,Enrolling by invitation,Barrett Esophagus,Procedure: Baseline surveillance endoscopy|Procedure: Radiofrequency ablation|Procedure: Follow up endoscopy 1|Procedure: Follow up endoscopy 2|Procedure: Follow up endoscopy 3,"Change in the Percent of Mucosa Healed by Neosquamous Epithelium|Change in expression of genes associated with epithelial-mesenchymal transition, stem cells, and submucosal glands|Change in inflammatory cell infiltrate",Dallas VA Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,20.0,U.S. Fed,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,15-076,March 2016,May 2020,December 2020,"February 23, 2016",,"July 18, 2019","Baylor Scott and White Research Institute, Dallas, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States",192,,No Results Available,https://ClinicalTrials.gov/show/NCT02688114
NCT00810212,Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion,,Withdrawn,Degenerative Disc Disease|Degenerative Spondylolisthesis|Spinal Stenosis,Procedure: PLF with autograft|Genetic: PLF with NeoFuse,"To determine the safety of NeoFuse (allogeneic mesenchymal precursor cells [MPCs] when combined with MasterGraft Resorbable Ceramic granules as a carrier for posterolateral lumbar fusion (PLF) with instrumentation|To evaluate the overall fusion success with NeoFuse plus carrier compared to autograft using CT scans and x-ray of the involved lumbar spine levels and access the change in outcomes (ODI, SF-36) and pain (VAS)","Mesoblast, Ltd.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,0.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,MSB-SF002,November 2008,November 2011,November 2011,"December 18, 2008",,"November 7, 2014","Texas Back Institute, Plano, Texas, United States",193,,No Results Available,https://ClinicalTrials.gov/show/NCT00810212
NCT00549913,Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF),,Completed,Degenerative Disc Disease|Spondylolisthesis|Spinal Stenosis,Genetic: NeoFuse|Procedure: posterolateral spinal fusion with instrumentation,To determine the safety of NeoFuse (allogeneic mesenchymal precursor cells [MPCs]) when combined with MasterGraft Resorbable Ceramic Granules as a carrier for posterolateral lumbar fusion with instrumentation.|To evaluate the overall fusion success of the use of NeoFuse plus carrier compared to autograft in the same patient|To assess CT scan as a pilot measure of fusion for use in the pivotal study|To provide preliminary data to support dose selection,"Mesoblast, Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,6.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSF0106,October 2007,August 2013,September 2013,"October 26, 2007",,"November 7, 2014","Hospital for Special Surgery, New York, New York, United States",194,,No Results Available,https://ClinicalTrials.gov/show/NCT00549913
NCT03473301,A Study of UCB and MSCs in Children With CP: ACCeNT-CP,ACCeNT-CP,"Active, not recruiting",Cerebral Palsy,Biological: Infusion of allogeneic umbilical cord blood|Biological: Infusion of MSCs,GMFM-66 score 12 months after study infusion|Adverse events,"Joanne Kurtzberg, MD|The Marcus Foundation|Duke University",All,24 Months to 60 Months   (Child),Phase 1|Phase 2,90.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Pro00089362,"April 9, 2018",May 2020,May 2021,"March 22, 2018",,"June 7, 2019","Duke University Medical Center, Durham, North Carolina, United States",195,,No Results Available,https://ClinicalTrials.gov/show/NCT03473301
NCT01290367,Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain,,Completed,Degenerative Disc Disease,Biological: Single Dose MPCs Injection|Procedure: Single injection of saline solution|Procedure: Single injection of hyaluronic acid,"To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).|To evaluate the change of treated lumbar intervertebral discs using Magnetic Resonance Imaging (MRI) at 6 months post injection of MPCs.|To evaluate the effectiveness of MPCs in reducing chronic lumbar back pain using the visual analog scale (VAS).","Mesoblast, Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,100.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",MSB-DR001,August 2011,July 2013,July 2015,"February 7, 2011",,"August 20, 2019","Arizona Pain Specialists, Scottsdale, Arizona, United States|UC Davis Spine Center, Sacramento, California, United States|The Spine Institute, Santa Monica, California, United States|IPM Medical Group, Inc., Walnut Creek, California, United States|Denver Spine, Denver, Colorado, United States|Rocky Mountain Associates in Orthopedic Medicine, P.C., Loveland, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina, United States|Central Texas Spine Institute, Austin, Texas, United States|Richmond Bone and Joint Clinic, Memorial Hermann Medical Group, Richmond, Texas, United States|Virginia Spine Research Institute, Inc., Richmond, Virginia, United States|Washington Center for Pain Management, Edmonds, Washington, United States|The Center for Pain Relief, Inc., Charleston, West Virginia, United States|Monash Medical Center, Clayton, Victoria, Australia",196,,No Results Available,https://ClinicalTrials.gov/show/NCT01290367
NCT02337517,Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease,,Terminated,Chronic Graft Versus Host Disease,Other: Laboratory Biomarker Analysis|Drug: Vismodegib,Failure free survival (FFS)|Incidence of adverse events|Change in National Institutes of Health (NIH) global score of chronic graft-versus-host disease (GVHD) defined by using the National Institutes of Health (NIH) consensus criteria for assessment of chronic graft-versus-host disease (GVHD) severity|One-year non relapse mortality (NRM)|One-year relapse rate|One-year failure free survival (FFS)|One-year overall survival|Clinical characteristics that may be associated with decreased failure free survival (FFS),"National Cancer Institute (NCI)|Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,6.0,NIH|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2014-02672|IIT 9664|84584|9664|P30CA042014,"September 8, 2015","December 31, 2018","December 31, 2018","January 13, 2015",,"February 8, 2019","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",197,,No Results Available,https://ClinicalTrials.gov/show/NCT02337517
NCT00927784,Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD,,Terminated,Heart Failure,Biological: Mesenchymal Precursor cells (RevascorTM)|Drug: Cryoprotective media alone,Incidence of Infectious Myocarditis|Incidence of Myocardial Rupture|Incidence of Neoplasm|Incidence of Hypersensitivity Reaction|Incidence of Immune Sensitization|Assessment of LVAD Wean|Incidence of Study Intervention-related Adverse Events|Incidence of All Serious Adverse Events|Number of Patients Who Experienced Donor-specific HLA Sensitization|Incidence of Myocardial Neovascularization at Time of Explant|Incidence of Cardiomyocyte Regeneration at Explant|Incidence of Cell Engraftment and Fate at Explant|Incidence of Survival to Cardiac Transplantation,"Icahn School of Medicine at Mount Sinai|National Heart, Lung, and Blood Institute (NHLBI)|Angioblast Systems",All,"18 Years and older   (Adult, Older Adult)",Phase 2,10.0,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",GCO 08-1093|P50HL077096,August 2009,May 2010,February 2011,"June 25, 2009","March 5, 2019","March 5, 2019","Sharp Memorial Hospital, San Diego, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Jewish Hospital, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Intermountain Medical Center, Salt Lake City, Utah, United States|Sacred Heart Medical Center, Spokane, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States",198,,Has Results,https://ClinicalTrials.gov/show/NCT00927784
NCT02336230,"A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD",,Completed,Grade B aGVHD|Grade C aGVHD|Grade D aGVHD,Drug: remestemcel-L,"To evaluate the efficacy of remestemcel-L in pediatric subjects with Grades B-D aGVHD who have failed to respond to steroid treatment post allogeneic HSCT (Overall Response Rate)|To gather additional information on the safety of remestemcel-L in pediatric subjects with Grades B-D aGVHD that have failed to respond to steroid treatment post allogeneic HSCT (Adverse events, SAE, Infusional toxicity, Formation of ectopic tissue foci|To determine the correlation between response to remestemcel-L at Day 28 and survival at Day 100|To measure the functional status of remestemcel-L-treated subjects using the Karnofsky/Lansky scale","Mesoblast International Sàrl|Quintiles, Inc.|Mesoblast, Ltd.",All,2 Months to 17 Years   (Child),Phase 3,55.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MSB-GVHD001,January 2015,January 2018,"April 2, 2018","January 12, 2015",,"February 11, 2019","Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital Colorado Center for Cancer/Blood Disorders, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children of the Nemours Foundation, Wilmington, Delaware, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Nemours Children's Specialty Care, Jacksonville, Florida, United States|Miami Children's Research Institute, Miami, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Cohen Children's Medical Center of NY, New Hyde Park, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Albert Einstein College of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",199,,No Results Available,https://ClinicalTrials.gov/show/NCT02336230
NCT01861054,Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients,,Terminated,Breast Cancer,Drug: Reparixin,"Markers of Cancer Stem Cells (CSCs) in the primary tumor and the tumoral microenvironment|Serine-threonine protein kinase (AKT)|Focal adhesion kinase (FAK)|CXCR1 levels|interleukin-1beta [IL-1beta]|interleukin-6 [IL-6]|tumor necrosis factor-alpha [TNF-alfa]|granulocyte macrophage colony stimulating factor [GM-CSF]|IL-8|CD4, CD8, NK and Macrophages|PK profile of the treatment|Vital signs (Blood Pressure, Heart rate, Body Temperature)|Hematology parameters (hemoglobin, white blood cell (WBC) and differential count, platelets)|Clinical chemistry parameters (sodium, potassium, calcium, serum creatinine, total protein, albumin, aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], urea, total bilirubin)|Urinalysis (pH, specific gravity and dipstick)",Dompé Farmaceutici S.p.A,Female,"18 Years and older   (Adult, Older Adult)",Phase 2,20.0,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,REP0210,February 2013,March 2015,"March 1, 2016","May 23, 2013",,"October 18, 2017","Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|University of Kansas Cancer Center, 4350 Shawnee Mission Pkwy, Suite 1500, Mailstop 6004, Fairway, Kansas, United States|The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Montefiore Medical Center, MMC Medical Park at Eastchester, The Bronx, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Sara Cannon Research Institute, Nashville, Tennessee, United States|The Methodist Hospital Research Institute, Houston, Texas, United States",200,,No Results Available,https://ClinicalTrials.gov/show/NCT01861054
NCT02032004,Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.,DREAM HF-1,"Active, not recruiting",Chronic Heart Failure,Biological: Allogeneic Mesenchymal Precursor Cells (MPC)|Other: Sham Comparator,"Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).|Time-to-first terminal cardiac event (TCE)|Time-to-hospital admissions for non-fatal decompensated HF events|Time-to-urgent care outpatient HF visits|Time-to-successfully resuscitated cardiac death (RCD) events|Total length of in-hospital stay in intensive care unit for non-fatal decompensated HF events|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, and successfully RCD events)|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, successfully RCD events or TCE)|Time-to-cardiac death|Time-to-all-cause death|Time-to-first non-fatal MI (myocardial infarction), non-fatal CVA (cerebrovascular attack) or coronary artery revascularization|Left Ventricular (LV) remodeling in LVESV determined by 2-D echocardiography|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and clinical outcomes|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and change in Month 6 to baseline LVESV and clinical outcomes|LV remodeling in LVEDV determined by 2-D echocardiography|Overall Left Ventricular systolic performance as assessed by LVEF (RVG or echocardiogram)|Functional exercise capacity as assessed by 6 Minute Walk Test|Functional status by New York Heart Association (NYHA) class|Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire|Quality of Life Measure - EuroQoL 5-dimensional (EQ-5D) questionnaire|Safety as assessed by occurrence of adverse events related to the index cardiac catheterization on Day 0|Safety as assessed by occurrence of treatment-emergent adverse events|Safety as assessed by clinical laboratory tests (serum chemistry - ALT, AST, alkaline phosphate, GGT, LDH, BUN, creatinine, uric acid, total bilirubin - and hematology - hematocrit, hemoglobin, WBC, eosinophils, ANC, platelet count)|Safety as assessed by urinalysis (blood, glucose, ketones, total protein)|Safety as assessed by vital signs (pulse, systolic BP, diastolic BP)|Safety as assessed by 12-lead electrocardiogram (ECG) findings - QTcF, QTcB, QT, QRS complex, HR and T waves.|Safety as assessed by telemetry monitoring findings (clinically significant arrhythmias)|Safety as assessed by rhythm analysis (specifically, ventricular arrhythmias) by interrogation of any implanted device capable of defibrillation|Safety as assessed by 24-hr Holter monitoring (HR, rate & duration of arrhythmias, a-fib average rate, supra- & ventricular ectopy singles/couplets/runs/totals, sustained & non-sustained ventricular tachycardia, longest pauses RR duration, total pauses)|Safety as assessed by physical examination findings judged as clinically significant changes from baseline by the investigator or newly occurring abnormalities (including weight)|Safety as assessed by important cardiovascular events from adjudicated data","Mesoblast, Inc.|Mesoblast, Ltd.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,566.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSB-MPC-CHF001,January 2014,December 2019,December 2019,"January 9, 2014",,"April 5, 2019","Mesoblast Investigational Site 10757 - Cardiology, P.C., Birmingham, Alabama, United States|Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa, Mesa, Arizona, United States|Mesoblast Investigational Site 10756 - Mayo Clinic, Phoenix, Arizona, United States|Mesoblast Investigational Site 13023 - University of Arizona Medical Center, Tucson, Arizona, United States|Mesoblast Investigational Site 10754 - University of California, San Diego, La Jolla, California, United States|Mesoblast Investigational Site 10759 - Scripps Clinic, La Jolla, California, United States|Mesoblast Investigational Site 13265 - University of California, Los Angeles, Los Angeles, California, United States|Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation, Los Angeles, California, United States|Mesoblast Investigational Site 10778 - Orange County Cardiology, Orange, California, United States|Mesoblast Investigational Site 13031 - St. John's Regional Medical Center, Oxnard, California, United States|Mesoblast Investigational Site 13275 - Stanford University Hospital, Stanford, California, United States|Mesoblast Investigational Site 13267 - Bethesda Heart Hospital, Boynton Beach, Florida, United States|Mesoblast Investigational Site 10780 - Morton Plant Hospital, Clearwater, Florida, United States|Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida, Gainesville, Florida, United States|Mesoblast Investigational Site 13273 - University of Florida Health, Jacksonville, Florida, United States|Mesoblast Investigational Site 10768 - University of Miami, Miami, Florida, United States|Mesoblast Investigational Site 13280, Orlando, Florida, United States|Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute, Tampa, Florida, United States|Mesoblast Investigational Site 13027 - Emory University School of Medicine, Atlanta, Georgia, United States|Mesoblast Investigational Site 10765 - Georgia Regents University, Augusta, Georgia, United States|Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center, Chicago, Illinois, United States|Mesoblast Investigational Site 13030 - University of Iowa, Iowa City, Iowa, United States|Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky, Lexington, Kentucky, United States|Mesoblast Investigational Site 13022 - University of Louisville, Louisville, Kentucky, United States|Mesoblast Investigational Site 13266, New Orleans, Louisiana, United States|Mesoblast Investigational Site 10782, Boston, Massachusetts, United States|Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Mesoblast Investigational Site 10762 - Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Mesoblast Investigational Site 10761 - Mayo Clinic, Rochester, Minnesota, United States|Mesoblast Investigational Site 13281, Las Vegas, Nevada, United States|Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center, Newark, New Jersey, United States|Mesoblast Investigational Site 10776 - Columbia University Medical Center, New York, New York, United States|Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System, Charlotte, North Carolina, United States|Mesoblast Investigational Site 10781 - Duke University, Durham, North Carolina, United States|Mesoblast Investigational Site 10758 - The Christ Hospital, Cincinnati, Ohio, United States|Mesoblast Investigational Site 10770 - University of Cincinnati, Cincinnati, Ohio, United States|Mesoblast Investigational Site 10773, Cleveland, Ohio, United States|Mesoblast Investigational Site 13278 - OhioHealth Research Institute, Columbus, Ohio, United States|Mesoblast Investigational Site 10785 - Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Mesoblast Investigational Site 13261 - University of Pennsylvania, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 10767 - Temple University Hospital, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 13277, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 10774 - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Mesoblast Investigational Site 10777 - Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Mesoblast Investigational Site 13024 - Austin Heart, PLLC, Austin, Texas, United States|Mesoblast Investigational Site 13274 - Soltero CV Research Center, Baylor Scott & White Research Institute, Dallas, Texas, United States|Mesoblast Investigational Site 10755 - Texas Heart Institute, Houston, Texas, United States|Mesoblast Investigational Site 13268 - Houston Methodist Hospital, Houston, Texas, United States|Mesoblast Investigational Site 10763 - University Hospital, Salt Lake City, Utah, United States|Mesoblast Investigational Site 10771 - Heart & Vascular Research, Swedish Medical Center, Seattle, Washington, United States|Mesoblast Investigational Site 10764 - University of Wisconsin, Madison, Wisconsin, United States|Mesoblast Investigational Site 10769 - Aurora Healthcare, Milwaukee, Wisconsin, United States|Mesoblast Investigational Site 13279, Milwaukee, Wisconsin, United States|Mesoblast Investigational Site 10789 - Aspirus Research Institute, Wausau, Wisconsin, United States|Mesoblast Investigational Site 11027, Edmonton, Alberta, Canada|Mesoblast Investigational Site 11024 - Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|Mesoblast Investigational Site 11025 - St. Michael's Hospital, Toronto, Ontario, Canada",201,,No Results Available,https://ClinicalTrials.gov/show/NCT02032004
